Prostaglandins and Other Lipid Mediators

Cytochrome P450 derived epoxidized fatty acids as a therapeutic tool against neuroinflammatory diseases.

--Manuscript Draft--

Manuscript Number:	PRO_2019_43R1
Article Type:	IG006042:Review Article
Keywords:	Stroke; Alzheimer's Disease (AD); Neuroinflammation; Depression; soluble epoxide hydrolase (sEH); Epoxyeicosatrienoic acid (EET); Parkinson's Disease (PD)
Corresponding Author:	Bruce Hammock University of California, Davis Davis, California United States
First Author:	Jogen Atone
Order of Authors:	Jogen Atone
	K Wagner
	Kenji Hashimoto
	Bruce Hammock
Abstract:	Cytochrome P450 (CYP) metabolism of arachidonic acid (ARA) produces epoxy fatty acids (EpFAs) such as epoxyeicosatrienoic acids (EETs) that are known to exert protective effects in inflammatory disorders. Endogenous EpFAs are further metabolized into corresponding diols by the soluble epoxide hydrolase (sEH). Through inhibition of sEH, many studies have demonstrated the cardioprotective and renoprotective effects of EpFAs; however, the role of sEH inhibition in modulating the pathogenesis of neuroinflammatory disorders is less well described. In this review, we discuss the current knowledge surrounding the effects of sEH inhibition and EpFA action in neuroinflammatory disorders such as Parkinson's Disease (PD), stroke, depression, epilepsy, and Alzheimer's Disease (AD), as well as the potential mechanisms that underlie the therapeutic effects of sEH inhibition.
Response to Reviewers:	Reviewer 1 A masterful and incredibly well written review showcasing some of the highlights and pitfalls associated with EETs and she and its inhibitors across various neurological pathologies. It was a pleasure to read. Reviewer 2 This manuscript is a clear and comprehensive review on the interest of targeting epoxy fatty acids for the treatment of neuroinflammatory diseases. I have only some suggestions that could enhance further the quality of the paper. 1.First, although inflammation is a common mechanism involved in all diseases mentioned in the manuscript, the pathophysiology is really different between neurodegenerative diseases such as Alzheimer and Parkinson disease, "vascular" diseases (stroke) ... I would suggest to add headings and aggregate these diseases. We agree with the reviewer's comment about the distinction between neurovascular and neurodegenerative disorders. We have moved the stroke section to be under a section named "Neurovascular Disorder," and the rest of the disorders (Parkinson's Disease, Alzheimer's Disease, epilepsy, and depression) under a section named "Neurodegenerative Disorders." 2.Secondly, it could help the reader to have a table regrouping the main information for each disease (model, intervention, effect, cellular mechanism and references for example). We agree with the reviewer's comment about adding a table to summarize information found in the manuscript. We have added two tables, one focusing on the organismal and organ level effects, and another focusing on the cellular level effects.

Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation

Highlights

- Soluble epoxide hydrolase inhibition and epoxy fatty acids are neuroprotective
- The mechanisms are diverse, involving attenuation of ER and mitochondrial stress
- EpFAs and sEH inhibition may be therapeutic against neuroinflammatory diseases

Abstract

Cytochrome P450 (CYP) metabolism of arachidonic acid (ARA) produces epoxy fatty acids (EpFAs) such as epoxyeicosatrienoic acids (EETs) that are known to exert protective effects in inflammatory disorders. Endogenous EpFAs are further metabolized into corresponding diols by the soluble epoxide hydrolase (sEH). Through inhibition of sEH, many studies have demonstrated the cardioprotective and renoprotective effects of EpFAs; however, the role of sEH inhibition in modulating the pathogenesis of neuroinflammatory disorders is less well described. In this review, we discuss the current knowledge surrounding the effects of sEH inhibition and EpFA action in neuroinflammatory disorders such as Parkinson's Disease (PD), stroke, depression, epilepsy, and Alzheimer's Disease (AD), as well as the potential mechanisms that underlie the therapeutic effects of sEH inhibition.

Acknowledgements and Conflicts of Interest:

Acknowledgments: This work was supported by the National Institute of Environmental Health Sciences (NIEHS) Grant R01 ES002710, NIEHS Superfund Research Program P42 ES004699, NIEHS T32 ES007059 (J.A), and AMED JP18dm0107119 (K.H.) The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of interest statement: BD Hammock is a founder and KM Wagner is an employee of EicOsis L.L.C., a startup company advancing sEH inhibitors into the clinic.

INTRODUCTION

Cytochrome P450s (CYP450) are recognized to be a large family of heme containing enzymes active in the metabolism of both xenobiotics and endogenous substrates [1]. The enzymes were named due to their chromophore nature that was observed with an emittance peak at 450 nm when bound to carbon monoxide. Historically their importance was demonstrated in mediating Phase I metabolism of xenobiotics including pharmaceutical therapies and pesticides, however their oxidation of endogenous substrates is now understood as an important cell signaling mechanism [2]. Here we review specifically the action of the epoxidized fatty acid metabolites resulting from CYP450 action on long chain parent polyunsaturated fatty acids (PUFAs). While a large body of literature describes the metabolites of arachidonic acid (ARA), we will expand this review to include what is known about the biological action of the omega-3 long chain PUFAs when available.

ARA metabolites have a wide range of actions, modulating inflammation, cell proliferation, angiogenesis, and immune response [3]. ARA and its 20-carbon metabolites are together termed eicosanoids, with much of research historically focusing on the role of prostaglandins (PGs) and leukotrienes (LTs) and their role in inflammation, vasodilation/vasoconstriction, apoptosis, and leukocyte trafficking among others, via a mechanism of activating G-protein coupled receptors (GPCRs) [4-6]. Prostaglandins and leukotrienes are synthesized from cyclooxygenase (COX) and lipoxygenase (LOX) metabolism of ARA, respectively, and COX or LOX inhibition have long been strategies of pharmacological intervention against inflammatory disorders, with varying degrees of success [7-11].

The biological functions of CYP450 derived epoxidized eicosanoids are less well described compared to prostaglandins; however, more evidence is accumulating in recent years regarding

their anti-inflammatory and vasorelaxant properties [12]. These may include epoxyeicosanoids such as the epoxyeicosatrienoic acids (EETs) and the eicosapentaenoic acid (EPA) derived epoxyeicosatetraenoic acids (EEQs). Although distinct from eicosanoids given their 22-carbon chain length, the docosahexaenoic (DHA) derived epoxydocosapentaenoic acids (EDPs) are also considered CYP450 derived epoxy fatty acids (EpFAs). In addition, it is likely that similar metabolites of less abundant fatty acids will also demonstrate biological action. While these CYP450 synthesized EpFAs share similar biological activity as well as the hydrolytic pathway by the soluble epoxide hydrolase (sEH) enzyme and to a lesser degree the microsomal epoxide hydrolase (mEH) enzyme, there are differences in the substrate affinity and activity among the regioisomers of each PUFA metabolites [13-15]. Regardless, most of these EpFAs are relatively stable to chemical hydrolysis and nucleophilic substitution and are for the most part transformed by sEH activity [14]. However, in the absence of sEH, β-oxidation, chain elongation, and omega, omega-1 and other hydroxylation reactions become dominant. Increasingly, reincorporation into glycerides, membrane incorporation and other pathways are being found to be important.

CYP450 derived eicosanoids also include the ω-hydroxylated 20-hydroxyeicosatrienoic acids (HETEs). The CYP4A and CYP4F subfamily derived 20-HETEs are noteworthy due to their vasoconstrictive role through inhibiting Ca^{2+} activated K^+ channels (K_{Ca}) and inhibiting renal Na^+-K^+-ATPases [16]. Abating 20-HETE synthesis has a therapeutic effect against hypertensive and ischemic injury, and therefore a clinical application of this strategy in disorders such as stroke and hypertension is under investigation [17, 18]. The omega and omega-1 hydroxylation occurs with omega-3 fatty acids as well but no biological role is yet established. In a similar vein, EETs have been demonstrated to regulate vascular tone through binding to K_{Ca} channels, TRPV4 channels,

Na^+-K^+-ATPases, thromboxane receptor activation, and activating the Gα mediated cAMP/PKA pathway [19-23].

Production of EETs is well characterized, whereby ARA is first cleaved off of membrane phospholipids by calcium-independent phospholipase A2 (iPLA2) or inducible phospholipase A2 (cPLA2) [24, 25]. Less well studied is their release by other enzymes such as diacylglycerol lipase. Free ARA is then epoxidized by various CYP450s including the CYP2C and 2J subfamilies [26]. ARA is converted by CYP450s into four regioisomers of EETs depending on the location of the double bond where the oxygen is inserted namely, 14,15-EET, 11,12-EET, 8,9-EET, and 5,6-EET. In the case of the CYP2J, it has been demonstrated that the oxidation of ARA to 14,15-EET is preferred over other regioisomers [27]. The EETs are subsequently hydrolyzed by the sEH (Figure 1) [28]. The sEH enzyme is a major regulatory enzyme for all the EpFAs converting them into corresponding vicinal diols, specifically for EETs into the dihydroxytrienoic acids (DHETs) which lack the biological function of EETs. The sEH catalysis of EETs and all EpFAs is rapid and the major route of their conversion, thereby altering the biological effects they exert. Alternatively, EETs have other elimination pathways as mentioned above where they undergo β-oxidation to form a 16-carbon hexadecadienoic acid or elongate to form a 22-carbon docosatrienoic acid [29].

Genetic ablation of sEH as well as pharmacological inhibition of sEH through highly potent and selective inhibitors increases the bioavailability of EpFA by blocking the conversion of EpFA to diols. Significant effort in increasing the bioavailability and stability of sEH inhibitors has resulted in molecules such as 1-(4-trifluoro-methoxy-phenyl)-3-(1-propionylpiperidin-4-yl)urea (TPPU) give sub-nanomolar potency even following oral administration [30]. TPPU, as an example of the optimized compounds, has demonstrated low to moderate blood brain barrier (BBB) penetration with distribution into the brain, though oral administration results in a higher

percentage of TPPU in the liver and the heart [31]. While sEH inhibitors are thought to increase the local concentration of bioactive EETs, it is important to note that they also increase levels of epoxygenated EPA and DHA metabolites systemically and diminish diol concentrations. Although DHETs are usually regarded as the inactive metabolite of EETs, DHETs may have some biological functions. For example, 11,12- and 14,15-DHETs have been shown to contribute to monocyte chemotaxis in presence of MCP-1 [32], indicating the possibility that the effect of sEH inhibition may be partially mediated by the lack of DHET activity. Inhibition of sEH can also prevent formation linoleate derived leukotoxin diols, which have been shown to exert greater toxicity than their corresponding epoxides through opening of mitochondrial pore transition and facilitating the release of cytochrome c [33, 34]. They also lead to increased permeability of vascular endothelium and pulmonary epithelium. Thus, investigation of the biological function of PUFA diols will result in a more comprehensive understanding of the underlying mechanism of sEH inhibition. Furthermore, sEH efficiently hydrolyzes DHA and EPA derived epoxides as well as ARA epoxides [14]. While the *in vivo* concentration of these fatty acids are dependent on diet, ARA and DHA in a brain are roughly similar in proportion compared to the concentration of EPA, which is lower than the ARA or DHA [35, 36]. The brain and plasma concentrations of EPA, DHA and their metabolites, however, are greatly responsive to dietary omega-3 supplementation [35, 37]. Therefore, biological effects of EDPs and EEQs should be taken into consideration when assessing the effect of sEH inhibition. Furthermore, the proportion of linoleic acid has increased dramatically in the Western diet since the early 20th century, and sEH inhibition may have a notable effect on the levels of linoleate diols which are known to exert toxic effect on cells [33, 34, 38].

Presence of sEH and bioactive epoxide in the central nervous system

Relative abundance of sEH can vary depending on species, sex, cell type, exposure to hormonal signals and inflammatory conditions among other factors [39-43]. For example, testosterone and the peroxisome proliferator-activated receptor (PPAR) agonist clofibrate have been shown to increase sEH levels in mouse kidney and liver [39]. Other PPAR agonists such as rosiglitazone and troglitazone have also been shown to increase sEH levels in murine adipose tissue but not in kidney or liver [40]. In the central nervous system (CNS), postmortem analyses of patients with disorders such as depression, bipolar disorder, schizophrenia, and Lewy body dementia show increased sEH protein expression, suggesting a possible link between sEH expression and neuroinflammation [41, 42]. A similar increase in sEH in inflamed tissue is so widely observed that the sEH protein may emerge as a marker of inflammation. Investigation of the baseline sEH expression in human CNS using immunohistochemical (IHC) staining indicates a wide distribution of sEH in brain regions including the thalamus, hypothalamus, cerebellum, hippocampus, basal ganglia, as well as in the brain stem and spinal cord which implicates a wide range of spinal and supraspinal targets for sEH inhibition [44]. In addition, sEH is present in various cell types including oligodendrocytes, endothelial cells, astrocytes, and neural cell bodies [44]. In contrast, Marowsky et al. 2009 has demonstrated through IHC staining of mouse brain that sEH appears in cerebral cortex, hippocampus, and striatum, though co-localized mostly in astrocytes rather than neurons, with the exception of the central amygdala [43]. While microglial sEH is not yet well characterized, sEH has been shown to be expressed in the BV2 microglial murine cell line [45]. Interestingly, sEH inhibition or ablation can suppresses microglial activation both *in vitro* and *in vivo,* indicating that sEH expression in microglia has a functional relevance in neuroinflammatory disorders [45]. The lack of neural sEH stain by Marowsky et al. 2009 may indicate species-specific differences in sEH localization, though it is possible that the results may

also vary depending on the antibody used [46]. While sEH expression is confirmed in rat cortical astrocytes [47], recent experiments in our laboratory using methods per Morisseau et al. 2000 [48] reveal sEH activity in rat primary cortical neurons comparable to that of astrocytes (Figure 2). Inhibition of sEH has a demonstrable anti-inflammatory effect in the CNS and has been shown to act on microglia, astrocytes, and neurons to prevent neuroinflammation [42, 45, 49].

Neuroinflammation is a complex process and can be necessary for clearance of debris, glial scar, and β-amyloid plaque among other cellular debris that could further the inflammatory process if left unmitigated [50, 51]. While understanding the scope of sEH inhibition in the CNS is not yet complete, a growing number of investigations are now focusing on the therapeutic potential of sEH inhibition in neuroinflammatory diseases. The current knowledge surrounding the effect of sEH inhibition in various neuroinflammatory disease models is summarized in Table 1. The most recent of these has demonstrated improvements in a preclinical model of autism spectral disorder specifically murine maternal immune activation [52]. In this review, we will present the current knowledge surrounding the effect of EpFAs and sEH inhibition in neuroinflammatory diseases with an emphasis on the possible cellular mechanisms that could underlie such effects.

NEUROVASCULAR DISORDER

While the site, duration, and the subtype (ischemic or hemorrhagic) of stroke may differ, all cases cause a temporary disruption of cerebral blood flow. This results in a reduction of ATP synthesis and Na^+/K^+ imbalance, glutamate excitotoxicity, and release of damage associated molecular patterns (DAMPs) by neurons that aid in recruitment of pathogenic lymphocytes such as NK cells [53-55]. In addition, stroke is associated with compromised BBB integrity, leukocyte adhesion and infiltration, iNOS upregulation, COX-2 upregulation, and inflammatory cytokine secretion [56]

Stroke

There is evidence indicating that inhibition of sEH elicits a protective effect against ischemic stroke in both rat and mice middle cerebral artery occlusion (MCAO) models [57, 58]. For example, oral administration of sEH inhibitors AUDA or *t*-AUCB results in a significantly diminished neural apoptosis and infarct size upon MCAO of stroke-prone spontaneously hypertensive and Wistar-Kyoto rats [59, 60]. In addition, Shaik et al. 2013 observed that rats pretreated with *t*-AUCB exhibit higher behavioral and neurological scores after MCAO even though they did not observe changes in cerebral blood flow [61]. Interestingly, although Dorrance et al. 2005 did not detect higher plasma and urinary EETs concentration after AUDA treatment [59], Shaik et al. 2013 did measure higher cortical EET to DHET ratios in brain cortices of MCAO rats treated with *t*-AUCB [61]. This discrepancy between plasma and cortical EETs level could be explained by the upsurge of PLA2 activity in cortex observed during cerebral ischemia [62], which could release membrane bound EETs or ARA for CYP450 metabolism into EETs. Furthermore, Tu et al. 2018 demonstrated that TPPU treatment upon focal ischemia in rats reduces the infarct volume, improves behavioral/neurological score, and reduces the upregulation of cytokine mRNA levels TNF-α and IL-1β caused by the ischemic stress [57]. These results suggest that the reduction in inflammation may mediate the effect of sEH inhibition on the infarct size reduction, although sEH inhibition also could be preventing the neural apoptosis directly. While the post-treatment effect on the infarct size is less robust than that observed through pre-treatment using *t*-AUCB [61], the results still suggest that sEH inhibitors are viable pharmacological tools for potential use in a clinical setting to mitigate damages associated with ischemic stroke.

EETs Increase VEGF and BDNF

The increased expression of vascular endothelial cell growth factor (VEGF) and brain derived neurotrophic factor (BDNF) can mediate the effect of sEH inhibition. VEGF overexpression is neuroprotective against intracerebral hemorrhage in mice [63], likely through the activation of the neuronal VEGFR2 and PI3K/AKT pathway [64]. Primary rat astrocytes treated with TPPU or *t*-AUCB releases significantly more VEGF under oxygen glucose deprivation (OGD) compared to the control conditions, and the effect is blocked by the addition of the EET antagonist 14,15-EEZE, suggesting that VEGF expression is EET dependent [49]. Furthermore, treatment of endothelial progenitor cells with *t*-AUCB increases VEGF and hypoxia-inducible factor (HIF-1α) in a dose dependent manner, an effect partially blocked by the PPAR-γ inhibitor GW9662 [65]. Since EPA dependent increase in VEGF expression involves a GPCR and PPAR-γ activation [66], it is plausible that EETs may also be acting in a similar fashion to induce VEGF expression. In addition, BDNF can also mediate the neuroprotective effect of sEH inhibition. For example, administration of AUDA for seven days following a MCAO treatment in mice increases the protein expression of mature BDNF, and sEH KO mice exhibit higher basal levels of BDNF receptor neuronal tropomyosin receptor kinase B (TrkB) and phosphorylated TrkB levels compared to wild type controls [67]. The effect of AUDA treatment on the MCAO infarct is abrogated by an intracerebroventricular injection of K252a, a Trk receptor antagonist [67]. While this evidence supports the view that induction of mature BDNF mediates the effect of sEH inhibition, more research is needed to exclude the possibility that other neurotrophins such as neurotophin-3 (NT-3) and nerve growth factor (NGF) may also be involved.

Regulation of BDNF is thought to act through a positive feedback loop involving phosphorylation of TrkB, cAMP response element-binding protein (CREB), calcium response element (CaRF1) dependent factors, along with various kinases [68, 69]. As such, an increase in

BDNF observed upon AUDA treatment may be mediated by or TrkB phosphorylation combined with GPCR activation and calcium influx into the cells. Interestingly, MCAO of sEH KO mice does not result in increased BDNF expression despite increased TrkB phosphorylation [67], suggesting that EETs may affect the TrkB phosphorylation state independent of BDNF.

EETs and Leukocyte Trafficking

Ischemic stroke can cause an accumulation of neutrophils, T-cells, and macrophage that facilitate the inflammatory response and exacerbate the outcome of a stroke [70]. The infiltration by activated T-cells and monocytes across the endothelial layer is facilitated by endothelial expression of adhesion molecules such as intracellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin [71] as well as by chemokines such as CCL2, CCL3, CINC-1, CXCL-12, and CX_3CL1 [72]. While exposure to cytokines such as TNF-α increase endothelial cell surface expression of VCAM-1, ICAM-1, and E-selectin, co-treatment with 11,12-EET can significantly reduce the expression of these adhesion molecules [73]. Furthermore, pretreatment of pulmonary artery endothelial cells with 11,12-EET or 14,15-EET prior to stimulation with inflammatory oxidized low-density lipoprotein results in reduction of ICAM-1, VCAM-1, and E-Selectin, as well as upregulation of CCL-2/MCP-1, both in terms of mRNA and protein expression [74]. This in turn may diminish accumulation of harmful leukocytes such as NK cells into the ischemic brain. In contrast, 5,6-EET can induce VCAM-1 and ICAM-1 expression in B-lymphocytes through TRPV4 dependent Ca2+-permeant nonselective cation channel (NSCC) activation [75], though this effect is not observed in endothelial cells [73]. Endothelial cells are also known to express TRPV4, suggesting that 5,6-EET have a cell-type specific effect on for adhesion molecule expression [76-78].

Interestingly, EETs may influence peripheral immune cells themselves, facilitating the resolution of neuroinflammation from the periphery. Incubation of THP-1 monocytic leukemia cells with 11,12-EET can attenuate IL-1β and phorbol-12-myristate-13-acetate (PMA) induced COX-2 protein induction, an effect likely mediated through the activation of PPAR-α [79]. This result is consistent with the fact that CYP450 inhibitor SKF525A or PPAR-α inhibitor GW6471 are independently capable of inducing COX-2 in these cells [79]. Furthermore, a study by Gilroy et al. 2016 has shown that CYP450 inhibition disrupts the resolution of zymosan induced inflammation by facilitating monocyte and polymorphonuclear cell accumulation, explained in part by the increased mRNA expression of chemotactic proteins: CCR2, CXCR1, and CCL2 [80]. The upregulation of CCL2 is also seen *ex vivo* in cultured peritoneal lavage cells treated with zymosan, and application of 14,15-EETs significantly reduces CCL2, iNOS, and IL-12 expression but not TNF-α [80]. Future studies may elucidate the degree to which EpFAs modulate inflammation and leukocyte infiltration through a detailed study characterizing the leukocyte inactivation.

NEURODEGENERATIVE DISORDERS

Neuroinflammation is a necessary process for both developing and mature brains, because it contributes to neurodevelopment during developmental stages, debris clearing upon injury, and immune conditioning against invasive pathogens in both developing and mature brains [81]. Nonetheless, neuroinflammation is thought to exacerbate the pathogenesis of neurodegenerative diseases such as the Parkinson's Disease, Alzheimer's Disease, epilepsy, and depression.

Parkinson's Disease

Parkinson's Disease (PD) is characterized by a significant loss of dopaminergic neurons along with increased inflammatory cytokines including interleukin 1β (IL-1β), interferon γ (IFN-

γ), and tumor necrosis factor alpha (TNF-α) [82, 83]. This is congruent with the fact that PD etiology includes the mutation of genes such as leucine-rich repeat kinase 2 (LRRK2) and environmental toxins such as the mitochondrial complex I inhibitor rotenone, factors that could intensify the inflammatory response in PD [84, 85]. Given this, several investigators have attempted to elucidate the therapeutic effect of sEH inhibition on PD pathogenesis.

Qin et al. 2015 has demonstrated that upon treating mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a precursor compound for the mitochondrial complex I inhibitor and redox cycler 1-methyl-4-phenylpyridinium (MPP+), the number of dopaminergic cells stained positive for tyrosine hydroxylase (TH) diminish and sEH immunoreactivity increases 14 days post treatment [86]. This neurotoxic effect of MPTP is attenuated by sEH gene knock out, pretreatment with the sEH inhibitor AUDA, and to a lesser degree 14,15-EET pretreatment. Interestingly, pretreatment with 14,15-EET *in vivo* does not elicit any additional benefit in mitigating dopaminergic TH^+ cell loss when administered to a sEH KO mice [86]. Ren al. 2018 has replicated these finding using TPPU [42]. TPPU decreases the endoplasmic reticulum (ER) stress protein phosphorylation response, decreases nitric oxide synthase (iNOS) protein expression, and increases superoxide dismutase (SOD) protein expression to levels comparable to the baseline [42]. In addition, genetic ablation of sEH mitigates the OX42 expression in striatum which represents microglia, macrophage, and leukocyte accumulation in response to MPTP treatment [42]. Furthermore, *in vitro* studies suggest that TPPU has a therapeutic effect directly on induced pluripotent stem cells (iPSC) with a parkin RBR E3 ubiquitin protein ligase (PARK2) mutation, preventing the increase in caspase-3 cleavage [42]. Finally, the effect of TPPU is prominent when administered after MPTP treatment whereas Qin et al. 2015 were unable to show therapeutic effect of the more rapidly metabolized AUDA 24-hour post MPTP [42, 86]. This may be due to the

differences in the physical and chemical properties between the two sEH inhibitors affecting their pharmacokinetic profiles and bioavailability. This is reasonable considering that unlike the current optimized sEH inhibitor TPPU, AUDA was synthesized to mimic 14,15-EET with a longer alkyl side chain, giving it a unique structure distinct from modern sEH inhibitors. [87] Interpretations of biological data using AUDA as a probe is complex because it is an EET mimic as well as an sEH inhibitor.

The sEH inhibitors could act either through mitigating microglial activation or preventing the initial neural damage caused by the MPTP. In a rotenone model of PD, *in vivo* rotenone treatment causes microglia activation as well as microglial dependent neuronal damage of dopaminergic neurons [88, 89]. MPP^+ can also induce microglial COX-2 expression and PGE_2 production in a primary neuron-glia culture [90]. Genetic ablation of sEH reduces traumatic brain injury (TBI) induced microglial activation in mice, and lipopolysaccharide (LPS) and IFN-γ induced inflammation in BV2 microglial cells is mitigated through AUDA treatment [45]. These lines of evidence suggest that sEH inhibition can act through modulating microglial activation. On the other hand, sEH inhibition can also act directly on neurons as well. For example, Lakkappa et al. 2019 has reported that N27 dopaminergic cells treated with an sEH inhibitor following a rotenone treatment exhibit a marked reduction in COX-1, COX-2, and IL-6 mRNA [91]. In addition, the authors have reported improved cell viability and increased expression of redox genes such as superoxide dismutase (SOD) and catalase (CAT) [91].

In addition to increased expression of redox genes, improved mitochondrial membrane potential may also underlie the effect of sEH inhibition. It is known that the entry of Ca^{2+} into cells through $Ca_V1.3$ L-type Ca^{2+} channels intensifies mitochondrial oxidation in dopaminergic neurons, and inhibition of these Ca^{2+} currents by a Ca^{2+} channel blocker such as isradipine reduces

mitochondrial oxidation in neurons [92]. Since 11,12-EETs block $Ca_V1.3$ L-type Ca^{2+} channels in a porcine cardiac muscle membrane enriched in L-type Ca^{2+} channels [93], improvement in mitochondrial membrane potential may be mediated by a diminished Ca^{2+} entry into dopaminergic cells [94]. Future studies should determine the relative contribution of EET mediated $Ca_V1.3$ blockade is the modulator of neuronal mitochondrial function.

Epilepsy

Inhibition of sEH may also play a role in mitigating seizures, since epilepsy is associated with increased inflammatory cytokine expression along with dysregulation of glutamatergic/GABAergic neurotransmission [95]. In a pilocarpine model of status epilepticus (SE) in rats, IL-1β protein expression increases in the frontal cortex, hippocampus, entorhinal cortex, and amygdala after SE onset, while immune cell presence such granulocytes and MHC-class II presenting microglia increase in the prefrontal cortex and hippocampus [96]. There is evidence of cytokines such as TNF-α inducing seizure in human patients during a clinical trial [97] and intensifying seizures in rats that have undergone amygdala kindling [98]. If inflammation does in fact contribute to the etiology of epilepsy, then sEH inhibition may mitigate seizure propensity or intensity. To test this hypothesis, Hung et al. 2015 treated mice that had undergone pilocarpine treatment or amygdala kindling with sEH inhibitors AUDA or TPPU, as well as with sEH genetic ablation [99]. As expected, AUDA and TPPU both diminished the increase in protein expression of IL-1β and IL-6, and reduced IκBα phosphorylation 7 days after SE onset [99]. However, the authors observed the threshold for seizure induction in kindled mice decreased only with AUDA treatment (a joint EET mimic/sEH inhibitor) but not with treatment of the pure sEH inhibitor TPPU [99]. In addition, sEH KO mice did not exhibit decreased inflammatory cytokine levels nor mitigate the ictogenic effect in either the pilocarpine model or the kindling model [99]. Conversely,

Inceoglu et al. 2013 demonstrated that sEH KO and the sEH inhibitors TPPU and TUPS are all capable of delaying $GABA_A$ receptor antagonists pentylenetetrazole (PTZ) and picrotoxin (PIC) induced seizures increasing the threshold for tonic seizures, which the authors hypothesized to be due to modulation of GABAergic signaling [100]. There is evidence suggesting that 11,12-EET can induce G-protein activated inwardly rectifying K+ (GIRK) channel activation in CA1 pyramidal neurons thus mitigating their excitatory post synaptic currents (EPSCs) [101]. However, such an effect is contrary to the excitatory effect of 14,15-EET in the CA1 region [102]. It may be that excitatory amino acid transporters (EAATs) are playing a role in mitigating seizures, because EAATs clear synaptic glutamate and minimize inappropriate firings and excitotoxic injuries [103, 104]. EAAT levels can be modulated by PPAR-γ agonists rosiglitazone or 15d-PGJ_2 [103]. Given this, the delayed seizure onset observed by Inceoglu et al. 2013 could be explained by increased EAAT expression on astrocytes. However, further research is needed to understand how EETs and PPAR-γ agonism may influence EAAT2 expression, and the dynamic relationship between PPAR-γ agonists and sEH levels in the brain, because PPAR agonists are known to induce sEH in some cells [39, 40]. It should be noted that the action of the sEH inhibitors is complicated by the lack of BBB penetration of different molecules. It also could be the sEH inhibitors are acting peripherally to increase EpFA which enter the brain as free fatty acids, glycerides, or even in macrophage. The role of inflammation in seizures is not well understood, and while sEH inhibitors appear anti-inflammatory and pro-resolving molecules, they could exacerbate seizure damage at one in time and mitigate it at another.

Depression

Inflammation is not a universal biomarker for depression; nonetheless, elevation of inflammatory cytokines in serum such as IL-6, IL-1β, and TNF-α is associated with an increased

propensity for depression [105]. Neuroinflammation in depressed patients may play a role in impaired neurogenesis, activation of the hypothalamic-pituitary-adrenal axis, and increased rate of tryptophan degradation by inducing indoleamine 2,3-dioxygenase (IDO), which decreases the availability of serotonin and melatonin [106]. Genetic risk for depression may include cytokine gene polymorphs. Bull et al. 2009 show that genetic polymorphism in IL-6 genotype make patients with chronic hepatitis C viral infection less susceptible to depressive symptoms induced by TNF-α treatment [107]. In addition, RNA microarray of post-mortem frontal lobes of patients diagnosed with major depression has indicated that cytokines including IFN-γ, IL-1α, IL-2, -3, -4, -5, -8 are upregulated, though interestingly the authors did not find any change in IL-6 expression [108].

The therapeutic mechanisms of antidepressants aim to increase the synaptic availability of monoamines, improve neuroplasticity and neurogenesis, increase BDNF, improve GABAergic neurotransmission, and reduce neuroinflammation [109]. Given that EETs are involved in reducing inflammation, facilitating hippocampal synapse formation, modulating neurogenesis, and increasing the production of growth factors such BDNF and VEGF, it is reasonable to assume that sEH inhibition and/or exogenous administration of EETs may help alleviate depressive symptoms. To test this hypothesis, Ren et al. 2016 induced depression like behavior in mice through repeated social defeat stress with and without TPPU to assess the antidepressant effect of the sEH inhibitor. They observed that the mice treated with TPPU spend more time swimming in the forced swim test, have diminished social avoidance behavior compared to vehicle controls, and show increase in BDNF production in their hippocampus [41, 110]. Accordingly, the authors observed an increase in BDNF and phosphorylated TrkB level in sEH KO mice, suggesting that the antidepressant effect of sEH inhibition/ablation is mediated through the BDNF-TrkB pathway. This research was followed by Wu et al. 2017, who showed that the mice treated with TPPU exhibit

increased markers of neurogenesis in the dentate gyrus as well as diminished forced swim scores upon treatment with the TrkB inhibitor K252a, confirming the results obtained by Ren et al. 2016. It is important to note, however, that Ren et al. did not find any changes in EETs concentration in hippocampus or frontal lobe of depressed mice. In possible future research, the incorporation of the EET antagonist 14,15-epoxyeicosa-5(Z)-enoic acid (EEZE) could demonstrate whether the effects of TPPU were mediated by the effect of 14,15-EET or to a lesser degree other regioisomers of EETs [111]. However, it is possible that the action of regioisomers of EEQs or EDPs may also be affected by 14,15-EEZE depending on the target protein for these EpFAs. Thus, much work is needed to test which regioisomers of any or all the EpFA classes could be the most efficacious against induced symptoms of depression.

Alzheimer's Disease

Neurodegeneration in Alzheimer's disease (AD) is defined by the aggregation of amyloid-β (Aβ) caused by cleavage of amyloid precursor protein (APP) primarily by β- and γ- secretases [112], accumulation of neurofibrillary tangles (NFTs) caused by tau phosphorylation, and mitochondrial dysfunction [113]. Aβ aggregation is thought to exert neurotoxicity through mitochondrial complex IV inhibition or through Toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) dependent microglial activation [114]. Risk genes for AD such as apolipoprotein E4 (ApoE4) can exacerbate the inflammatory effect of Aβ aggregates in microglia. However, in astrocytes ApoE4 may dampen the activation TLR, suggesting a cell type specific effect of ApoE in the brain [50, 115, 116]. Data examining the effect of sEH inhibition as therapeutic agents in an AD model is forthcoming, however published experiments with a flavonoid pinocembrin seems to have a therapeutic effect on APP/PS1 AD mice though a mechanism that may involve sEH inhibition (IC_{50}, 2.58 uM) [117, 118]. While four-month-old

APP/PS1 mice orally administered with pinocembrin 5 days a week showed no improvement in Aβ plaque formation, they have shown increased acetylcholine levels, improved BBB integrity, reduced RAGE dependent p38 mitogen-activated protein kinases (MAPK) activation, and reduced inflammatory markers including: GFAP, Iba-1, TNF-α, IL-1β, and IL-6 [117]. It is possible that anti-inflammatory effect of pinocembrin did not have an impact on the Aβ plaque clearance since astrocytic activation is vital for Aβ clearance [117]. In addition, Yao et al. 2016 has shown that pretreatment of HEK293 cells transfected with human tau gene prior to H_2O_2 treatment with TPPU significantly diminished the H_2O_2 induced tau hyperphosphorylation at Thr231 and Ser396 [119]. While the authors claim the effect may be mediated by the PI3K/AKT pathway activation, more research is needed to determine the mechanism underlying the effect of the sEH inhibitor TPPU. Regardless, the ability of TPPU to prevent tau hyperphosphorylation provides a clear indication that sEH inhibition may delay or mitigate AD pathology *in vivo*.

Effect of Aβ on Production of EETs

Brain CYP450 levels change depending on various factors including glutamate availability or inflammation [120, 121] and the inflammatory conditions in AD may affect the endogenous levels of EETs in the CNS. The oxylipin profile in an AD brain remains to be elucidated, however, when isolated rat brain microsomes along with primary astrocyte and hippocampal neuronal cultures are treated with Aβ42, CYP450 activity seem to decrease as total EET and DHET levels diminish [122]. In contrast, CYP450 metabolites including EETs are increased in the hippocampus of hAPP transgenic mice overexpressing human APP, though this can be attributed to the MEK/MAPK dependent PLA2 activation in response to Aβ as opposed to increase in CYP450 activity [123]. Mutating PLA2 mitigates hyperactivity, anxiety-related behavior, and premature mortality observed in hAPP mice, indicating that ARA metabolism dysregulation may contribute

to neurodegeneration in hAPP mice. More research is necessary to determine how sEH inhibition would affect the level of EETs and other EpFAs including their amides in the dysregulated state.

PUFAs and Hippocampal function

Proper hippocampal development is disrupted in AD pathogenesis [124], and epoxyeicosanoids such as EETs, DHA derived EDPs, and other EpFAs may serve as therapeutic tools to maintain hippocampal function. For example, 14,15-EET – but not 14,15-DHET – facilitates TPRV4 mediated calcium flux in primary rat hippocampal culture, promoting neurite outgrowth and axon maturation [125]. In addition, incubation of prefrontal cortex slice with 14,15-EETs or AUDA for 10 minutes enhances long-term potentiation and glutamate transmission, suggesting that EETs may play a role in synapse formation in a healthy brain [126]. Furthermore, the level of oxylipins earlier in the developmental stages can modulate hippocampal neurodevelopment by affecting the differentiation of neural stem cells (NSCs) [127]. *In vitro* application of selected individual regioisomers on NSCs indicate that application of ARA derived 11,12-EET to NSCs promote glial differentiation of NSCs, while the application of DHA derived 16,17-EpDPE promotes neural differentiation of NSCs [127]. Finally, the anti-inflammatory effect of EETs or EDPs may affect neural differentiation of NSCs as well, as inflammatory cytokines in the CNS such as IL-6 can disrupt hippocampal neurogenesis [128]. While the effect of EpFAs on hippocampal neurogenesis needs further investigation, sEH inhibition is a promising avenue for stimulating neurogenesis and synaptogenesis in the hippocampus of AD patients. Both an advantage and a caution stemming from these observations is that sEH inhibition will stabilize all EpFA so far tested, with relative stabilization depending on substrate concentration and structure [14].

CELL AND MOLECULAR MECHANISMS

Many studies indicate that the mechanisms of the action of EETs and other EpFA are diverse, involving PPARα/γ, TRPV4, Na^+, BK_{Ca}, L-type Ca^{2+} channel, and thromboxane receptor agonism among others; however, it is unclear what the primary mechanism of EETs could be in neuroinflammatory disorders [23, 129]. Potential mechanisms underlying EETs or sEHIs are summarized in Table 2. EETs mediated suppression of inflammation involves reduced activation of NF-κB, reduced phosphorylation of p38, and suppression of IκBα degradation [74]. Node et al. 1999 has demonstrated that TNF-α induced nuclear translocation of NF-κB in endothelial cells is blocked in the presence of 11,12-EET, and that both 11,12-EET and 14,15-EET prevents the degradation of IκB-α though inhibition of IκB kinase (IKK) activity [73]. Phosphorylation of IκB-α and nuclear translocation of NF-κB decreases with sEH inhibition in murine hearts from a transverse aortic constriction (TAC) model and cardiomyocytes, supporting the idea that IKK inhibition mediates the effect of EETs [130] While the regulation of IKK and IκBα is multifaceted, enzyme complex PP2A is implicated in inhibiting the kinase activity of IKKβ, the IKK subunit that mediates the canonical NF-κB pathway activation by proinflammatory stimuli [131, 132]. Since 11,12-EET, sEH KO, and *t*-AUCB treatment have been shown to upregulate PP2A activity in the cardiovascular system [133-135], PP2A activation may underlie the inhibition of IKK activity by EETs. However, more research is needed to elucidate how EETs and other EpFAs regulate the activities of IKK and NF-κB. While there are EpFA responsive GPCRs such as the newly identified GPR132 that is activated by EETs [136], there is evidence suggesting that GPR132 expression correlates with increasing inflammatory markers such as CCL-2, MMP-9, and COX-2 in breast cancer lesions [137]. Thus, its involvement in the anti-inflammatory effect of EETs may not be probable. Alternatively, EETs can exert their anti-apoptotic effect through ameliorating the mitochondrial damage. For example, sEH inhibition and exogenous EET

administration are shown to protect mitochondrial membrane potential from dissipating under laser-induced oxidative stress, as well as to preserve mitochondrial functional activity under starvation conditions [138, 139]. EETs are also shown to exert cardioprotective effects through activating the mitochondrial K_{ATP} channels, though more research is needed to determine its impact on mitochondrial health [140]. Preserving mitochondrial health through EETs could mitigate reactive oxygen species (ROS) production and release and the ER Stress response, ultimately contributing to the attenuation of multiple cellular damages associated with neuroinflammatory disorders [141-143].

Inceoglu et al. 2008 previously described that, in addition to mitigating LPS induced COX-2 mRNA expression, EETs can induce spinal steroidogenic acute regulatory protein (StARD1) mRNA expression possibly through the cAMP signaling pathway [144, 145]. Such increase in StARD1 can contribute to reduction in inflammatory response through increased mitochondrial production of 25-hydroxycholesterol, 27-hydroxycholesterol, and 5-cholesten-3β,25diol 3-sulfonate (25HC3S) [145, 146], which is thought to exert its anti-inflammatory and proliferative effects through PPAR-γ binding [147]. This effect was observed by Chen et al. 2018 as well, where stroke induced by injection of type IV collagenase into rat thalamus, a model for central pain, caused significant decrease in the StAR mRNA expression in the perilesion site of thalamus. In addition, an increase in paw sensitivity to mechanical stimuli was rescued by daily microinjection of 0.1 ug 14,15-EET for 3 days using an implanted canula [148]. However, since EETs are also known to activate PPAR-γ [149], it is unclear the magnitude by which the EETs mediated induction of StAR affects PPAR activity.

ER Stress in Neuroinflammation

Altering the ER stress pathway may be part of the therapeutic mechanism of EpFAs against neuroinflammatory disorders, since the inflammatory and ER stress pathways have shared molecular components. For example, Hu et al., 2006 demonstrated that an increase in proinflammatory cytokines such as TNF-α causes degradation of IκBα through association of IKK with ER stress sensor inositol-requiring enzyme (IRE1α) and TNF receptor associated factor (TRAF2) in the human breast cancer cell line MCF-7 [150]. This activation of IRE1α and TRAF2 is sufficient to induce NF-κB independent of TNFα, because ER stressors tunicamycin and thapsigargin activate NF-κB even when cells are treated with TNFR1-siRNA to block TNF signaling [150]. EETs are known to affect the phosphorylation state of these ER stress proteins. For example, Bettaiab et al., 2013 found that ER stress markers associated with consumption of high fat diet such as phosphorylation of IRE1 and ATF6 is significantly diminished in sEH KO mice. In addition, Inceoglu et al. 2015 has also observed a reduction in ER stress proteins in sciatic nerve upon systemic administration of TPPU in a tunicamycin rat model [151]. Similar results were obtained *in vitro* with sEH inhibition in HepG2 cells treated with thapsigargin [152]. Involvement of EETs in ER stress was also observed in human bronchial epithelial cells treated with cigarette smoke extracts, where the loss of viability and increased phosphorylation of ER stress proteins was reversed with pretreatment of 14,15-EET but not with 14,15-EEZE co-administration [153].

While the mechanisms of action of EETs on the ER stress pathway remain to be elucidated, there are several points of evidence. EETs may act partly through the AMPK-AKT pathway, as exposure of neonatal myocytes and HL-1 cardiac muscle cells to 14,15-EETs upon hypoxia/reoxygenation treatment results in an increased phosphorylation of AKT and increased PIP_3 concentration, indicating PI3K activity [154]. Activation of AKT can prevent ER-stress

induced cell death through upregulating inhibitors of apoptotic protein (IAP) family proteins cIAP-2 and XIAP [155], or through upregulation of mitochondrial Bcl-2, [156, 157] though the evidence of direct interaction has not yet been elucidated.

Regardless, the observed reduction in ER stress protein phosphorylation upon sEH inhibition indicates an integral role of EETs and other EpFAs against ER dysfunction. ER stress is a hallmark of many neuroinflammatory disorders including PD and AD [158-160], induced by number of factors including high glucose levels and exposure to ROS generating mitochondrial toxins [161, 162]. Clarifying the nature of involvement of EETs on ER stress is vital to our understanding of the mechanism of EETs and sEH inhibition.

CYP450 Derived Endocannabinoids: Beyond EETs

The primary focus of many researchers investigating the mechanism underlying sEH inhibition is on EETs. However, increasingly the literature refers broadly to EpFA because the term EETs is reserved for the monoepoxides of arachidonic acid. Inhibition of sEH can also involve the endocannabinoid (ECB) system, which has an anti-inflammatory component that is investigated vigorously to combat neuroinflammation [163, 164]. For example, Lastres-Becker et al. 2005 has shown that cannabinoid (CB) receptor agonists such as $^{9}\Delta$THC are neuroprotective against 6-hydroxydopamine induce dopaminergic cell death *in vivo* [163]. However, using a general CB agonist such as HU210 is not optimal as a long-term treatment because CB_1 receptor agonism may produce undesirable side effects such as impaired working memory [165]. A CB_2 agonist JWH-015 has a profound effect on IFN-γ induced CD40 expression as well as LPS induced TNF-α secretion in primary murine microglial culture, suggesting that CB_2 agonism may be a potent tool to combat neuroinflammatory conditions [166].

Inceoglu et al. 2007 has previously demonstrated that 5,6-EET can bind to CB_2 receptors, implicating a potential mechanism by which EETs and EET analogues could exert their effects on cells [167]. EET analogues are present in the ECB system; for example, anandamide (AEA) can be metabolized by the orphan enzyme CYP4X1 to one of 4 regioisomers of epoxyeicosatrienoic acid ethanolamide (EET-EA), whereas 2-arachidonoylglycerol (2-AG) can be metabolized to 14,15- and 11,12- epoxyeicosatrienoic glycerols (EET-G) by the CYP2J family [168, 169]. This can potentially shift the affinity of these ECBs to primarily favor CB_2 binding over CB_1 as well as improve their resistance to degradation. Illustrating this point, Snider et al. 2009 has shown that 5,6-EET-EA can be formed from AEA by microglia, and it has several orders of magnitude greater affinity for CB_2 receptor compared to AEA. The 5,6-EET-EA affinity for CB_1 receptor is diminished compared to AEA but it has an increased half-life from 14.3 minutes to 32.2 minutes when incubated in a mouse brain homogenate [170]. Similarly, epoxidation of EPA ethanolamide (EPEA) at the 17,18- position increases its potency against CB_2 receptors while lessening its potency for CB_1 receptors [171]. This effect is not observed for DHA derived 19,20-EDP-EA [171], possibly indicating that the epoxidation of eicosanoid ethanolamides in particular shifts their CB receptor affinity to favor CB_2 receptors. Because EET-EAs are ligands for sEH analogous to EETs, combination of sEH inhibition with fatty acid amide hydrolase (FAAH) inhibitors or monoglyceride lipase (MGL) inhibitors can potentially increase CB_2 selective EET-EAs [172]. In fact, Sasso et al., 2016 demonstrates that sEH and FAAH dual inhibition has a synergistic antinociceptive effect against carrageenan induced inflammatory pain and neuropathic pain, likely due to increased EET-EAs that possess significantly greater CB_2 affinity [173]. Finally, pretreating BV-2 microglia with 17,18-EEQ-EA and 19,20-EEQ-EA significantly reduces LPS induced IL-6 production and nitrite production through a CB mediated mechanism [171]. Further research may

find that the dual inhibition of sEH and FAAH and/or MGL could increase the concentration of these CB_2 activating EpFAs, mitigating neuroinflammation beyond the effect of sEH inhibition alone.

CONCLUSION

Neuroinflammation is a necessary process for debris clearance and proper neurodevelopment. However, it is evident that sEH and exogenous administration of EETs can ameliorate damage associated with an inflammatory disease models such as PD, depression, stroke, and epilepsy. They act through mechanisms that can involve PPARs, GPCRs, receptor tyrosine kinase (RTK) phosphorylation, and modulation of ion channels. Through these mechanisms, EpFAs and sEH inhibition may diminish intracellular ROS levels and ER stress mediated apoptosis, neuronal DAMP and cytokine release, and subsequent activation of glial cells such as astrocytes and microglia. Preventing glial activation mitigates the induction of inflammatory cytokines, chemokines, and cell adhesion molecules, in addition to averting disruption of glutamate/GABA homeostasis, all of which exacerbate neurodegeneration. Finally, further research may yield positive results for other neuroinflammatory disorders such as amyotrophic lateral sclerosis (ALS) because an ALS hallmark is increased ROS attributed to superoxide dismutase 1 (SOD1) mutation, mitochondrial and ER calcium dysregulation, downregulation of astrocytic EAAT2 and potential glutamate excitotoxicity [174] that could potentially be mitigated through sEH inhibition.

Wide spanning function of sEH against all classes of EpFA complicates the task of elucidating specific conclusions about the effect of EETs. By testing EDPs and EEQs in the same model systems, using sEH KO in conjunction with sEH inhibitors, utilizing more than one sEH inhibitor, and distinguishing the effects of all four regioisomers of EETs, we can develop a more accurate view of the effect of EpFAs against neuroinflammatory diseases. In addition, while the

discovery of a putative EET binding GPCR such as GPR132 is helpful in clarifying the mechanism underlying EETs, further exploration of a more selective GPCR for EETs regioisomers could shine light upon the functional distinction between EET regioisomers. In conclusion, sEH inhibition has been shown to be therapeutic against a wide array of disease models with neuroinflammation as a common pathology and neuronal loss possibly through multiple anti-inflammatory and pro-survival signaling pathways. Investigating the effect of sEH inhibitors against other neuroinflammatory diseases such as ALS or AD is therefore a promising avenue for further discoveries in both basic science as well as disease diagnosis.

Figure Legends

Figure 1. Polyunsaturated fatty acids (PUFAs) including arachidonic acid (ARA), eicosapentaenoic acid (EPA), and docosapentaenoic acid (DHA), can all be metabolized by cytochrome P450 to produce epoxyeicosatrienoic aids (EETs), epoxyeicosatetraenoic acids (EEQs), and epoxydocosapentaenoic acids (EDPs), respectively. All regioisomers of these anti-inflammatory metabolites can be hydrolyzed by soluble epoxide hydrolase (sEH) into corresponding diols. As such, sEH inhibition can bring about a significant change in the epoxide to diol ratio of DHA and EPA metabolites in addition to ARA derived metabolites. The diols are more polar, more easily excreted, and appear less beneficially active than their corresponding epoxides, and in some cases are pro-inflammatory. These PUFAs may alternatively be metabolized by cyclooxygenase (COX), and lipoxygenase (LOX) independently, or in some cases sequentially.

Figure 2. Enzymatic activity of sEH, measured as a rate of [^{3}H] *trans*-1,3-diphenylpropene oxide (*t*DPPO) hydrolysis using [3H] *t*DPPO at a final concentration of 50 μM. Activity was measured in primary rat cortical astrocytes and neurons harvested from neonatal rat pups. The sEH activity of primary neurons were comparable to that of astrocytes, indicating that sEH inhibitors may act

directly on rat neurons in addition to glia to prevent neural loss (bars represent ±1 SEM). Two tailed t-test, 10 df, ns.

Figure 3. Schematic representation of how epoxyeicosatrienoic acids (EETs) may exert their anti-inflammatory and anti-apoptotic effects. EETs are hypothesized to suppress the activation of NF-κB and ER stress pathways through various means including IKK inhibition and RTK signaling. Increased cAMP could facilitate neural survival through transcription of proteins such as brain derived neurotrophic factor (BDNF), which can amplify through a positive feedback loop, mitigating apoptosis. EETs may also act through regulating ion channels such as $Ca_V1.3$ and mitochondrial K_{ATP} channels, preventing apoptosis. EET regioisomers have differential affinity for activating various pathways, with cell type and receptor specific effects on inflammation and vasculature remodeling

Table 1. Studies describing the therapeutic effect of sEH inhibition against neuroinflammatory disorders. Inhibition of sEH is therapeutic in cases of PD, depression, and stroke, while effects on AD and epilepsy are not yet fully elucidated.

Table 2. Potential mechanisms of the therapeutic effect of EETs and/or sEH inhibition. While CYP metabolites of EPA or DHA are also known to have therapeutic effects, their mechanisms are not included in this table.

References

[1] D.W. Nebert, T.P. Dalton. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 6(12) (2006) 947-60.
[2] J.H. Capdevila, J.R. Falck. The CYP P450 arachidonic acid monooxygenases: from cell signaling to blood pressure regulation. Biochem Biophys Res Commun 285(3) (2001) 571-6.
[3] A. Konkel, W.H. Schunck. Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids. Biochim Biophys Acta 1814(1) (2011) 210-22.
[4] C.D. Funk. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294(5548) (2001) 1871-5.
[5] R. Nasrallah, J. Clark, R.L. Hebert. Prostaglandins in the kidney: developments since Y2K. Clin Sci (Lond) 113(7) (2007) 297-311.
[6] H.M. Sarau, R.S. Ames, J. Chambers, C. Ellis, N. Elshourbagy, J.J. Foley, D.B. Schmidt, R.M. Muccitelli, O. Jenkins, P.R. Murdock, N.C. Herrity, W. Halsey, G. Sathe, A.I. Muir, P. Nuthulaganti, G.M. Dytko, P.T. Buckley, S. Wilson, D.J. Bergsma, D.W. Hay. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol 56(3) (1999) 657-63.
[7] A. Samii, M. Etminan, M.O. Wiens, S. Jafari. NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies. Drugs Aging 26(9) (2009) 769-79.
[8] S.C. Vlad, D.R. Miller, N.W. Kowall, D.T. Felson. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70(19) (2008) 1672-7.
[9] M. Jatana, S. Giri, M.A. Ansari, C. Elango, A.K. Singh, I. Singh, M. Khan. Inhibition of NF-kappaB activation by 5-lipoxygenase inhibitors protects brain against injury in a rat model of focal cerebral ischemia. J Neuroinflammation 3 (2006) 12.
[10] O. Firuzi, J. Zhuo, C.M. Chinnici, T. Wisniewski, D. Pratico. 5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease. FASEB J 22(4) (2008) 1169-78.
[11] K.H. Kang, H.H. Liou, M.J. Hour, H.C. Liou, W.M. Fu. Protection of dopaminergic neurons by 5-lipoxygenase inhibitor. Neuropharmacology 73 (2013) 380-7.
[12] A.A. Spector, X. Fang, G.D. Snyder, N.L. Weintraub. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 43(1) (2004) 55-90.
[13] X. Fang, N.L. Weintraub, L.L. Stoll, A.A. Spector. Epoxyeicosatrienoic acids increase intracellular calcium concentration in vascular smooth muscle cells. Hypertension 34(6) (1999) 1242-6.
[14] C. Morisseau, B. Inceoglu, K. Schmelzer, H.J. Tsai, S.L. Jinks, C.M. Hegedus, B.D. Hammock. Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids. J Lipid Res 51(12) (2010) 3481-90.
[15] G. Zhang, D. Panigrahy, L.M. Mahakian, J. Yang, J.Y. Liu, K.S. Stephen Lee, H.I. Wettersten, A. Ulu, X. Hu, S. Tam, S.H. Hwang, E.S. Ingham, M.W. Kieran, R.H. Weiss, K.W. Ferrara, B.D. Hammock. Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A 110(16) (2013) 6530-5.
[16] D.L. Kroetz, F. Xu. Regulation and inhibition of arachidonic acid omega-hydroxylases and 20-HETE formation. Annu Rev Pharmacol Toxicol 45 (2005) 413-38.
[17] X. Han, X. Zhao, X. Lan, Q. Li, Y. Gao, X. Liu, J. Wan, Z. Yang, X. Chen, W. Zang, A.M. Guo, J.R. Falck, R.C. Koehler, J. Wang. 20-HETE synthesis inhibition promotes cerebral protection after intracerebral hemorrhage without inhibiting angiogenesis. J Cereb Blood Flow Metab (2018) 271678X18762645.
[18] J.M. Williams, S. Murphy, M. Burke, R.J. Roman. 20-hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension. J Cardiovasc Pharmacol 56(4) (2010) 336-44.
[19] S. Hu, H. Kim. Activation of K+ channel in vascular smooth muscles by cytochrome P450 metabolites of arachidonic acid. European Journal of Pharmacology 230(2) (1993) 215-221.

[20] S. Earley, T.J. Heppner, M.T. Nelson, J.E. Brayden. TRPV4 forms a novel Ca2+ signaling complex with ryanodine receptors and BKCa channels. Circ Res 97(12) (2005) 1270-9.
[21] T. Satoh, H.T. Cohen, A.I. Katz. Intracellular signaling in the regulation of renal Na-K-ATPase. II. Role of eicosanoids. J Clin Invest 91(2) (1993) 409-15.
[22] M.A. Carroll, A.B. Doumad, J. Li, M.K. Cheng, J.R. Falck, J.C. McGiff. Adenosine2A receptor vasodilation of rat preglomerular microvessels is mediated by EETs that activate the cAMP/PKA pathway. Am J Physiol Renal Physiol 291(1) (2006) F155-61.
[23] D.J. Behm, A. Ogbonna, C. Wu, C.L. Burns-Kurtis, S.A. Douglas. Epoxyeicosatrienoic acids function as selective, endogenous antagonists of native thromboxane receptors: identification of a novel mechanism of vasodilation. J Pharmacol Exp Ther 328(1) (2009) 231-9.
[24] F.A. Fitzpatrick, R. Soberman. Regulated formation of eicosanoids. J Clin Invest 107(11) (2001) 1347-51.
[25] A.A. Spector. Arachidonic acid cytochrome P450 epoxygenase pathway. J Lipid Res 50 Suppl (2009) S52-6.
[26] A.A. Spector, H.Y. Kim. Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism. Biochim Biophys Acta 1851(4) (2015) 356-65.
[27] J.P. Graves, M.L. Edin, J.A. Bradbury, A. Gruzdev, J. Cheng, F.B. Lih, T.A. Masinde, W. Qu, N.P. Clayton, J.P. Morrison, K.B. Tomer, D.C. Zeldin. Characterization of four new mouse cytochrome P450 enzymes of the CYP2J subfamily. Drug Metab Dispos 41(4) (2013) 763-73.
[28] N. Chacos, J. Capdevila, J.R. Falck, S. Manna, C. Martin-Wixtrom, S.S. Gill, B.D. Hammock, R.W. Estabrook. The reaction of arachidonic acid epoxides (epoxyeicosatrienoic acids) with a cytosolic epoxide hydrolase. Arch Biochem Biophys 223(2) (1983) 639-48.
[29] X. Fang, N.L. Weintraub, C.L. Oltman, L.L. Stoll, T.L. Kaduce, S. Harmon, K.C. Dellsperger, C. Morisseau, B.D. Hammock, A.A. Spector. Human coronary endothelial cells convert 14,15-EET to a biologically active chain-shortened epoxide. Am J Physiol Heart Circ Physiol 283(6) (2002) H2306-14.
[30] J.Y. Liu, Y.P. Lin, H. Qiu, C. Morisseau, T.E. Rose, S.H. Hwang, N. Chiamvimonvat, B.D. Hammock. Substituted phenyl groups improve the pharmacokinetic profile and anti-inflammatory effect of urea-based soluble epoxide hydrolase inhibitors in murine models. Eur J Pharm Sci 48(4-5) (2013) 619-27.
[31] A.I. Ostermann, J. Herbers, I. Willenberg, R. Chen, S.H. Hwang, R. Greite, C. Morisseau, F. Gueler, B.D. Hammock, N.H. Schebb. Oral treatment of rodents with soluble epoxide hydrolase inhibitor 1-(1-propanoylpiperidin-4-yl)-3-[4-(trifluoromethoxy)phenyl]urea (TPPU): Resulting drug levels and modulation of oxylipin pattern. Prostaglandins & other lipid mediators 121(Pt A) (2015) 131-7.
[32] S. Kundu, T. Roome, A. Bhattacharjee, K.A. Carnevale, V.P. Yakubenko, R. Zhang, S.H. Hwang, B.D. Hammock, M.K. Cathcart. Metabolic products of soluble epoxide hydrolase are essential for monocyte chemotaxis to MCP-1 in vitro and in vivo. J Lipid Res 54(2) (2013) 436-47.
[33] M.F. Moghaddam, D.F. Grant, J.M. Cheek, J.F. Greene, K.C. Williamson, B.D. Hammock. Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase. Nat Med 3(5) (1997) 562-6.
[34] M.F. Sisemore, J. Zheng, J.C. Yang, D.A. Thompson, C.G. Plopper, G.A. Cortopassi, B.D. Hammock. Cellular characterization of leukotoxin diol-induced mitochondrial dysfunction. Arch Biochem Biophys 392(1) (2001) 32-7.
[35] J.T. Wood, J.S. Williams, L. Pandarinathan, D.R. Janero, C.J. Lammi-Keefe, A. Makriyannis. Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma. J Lipid Res 51(6) (2010) 1416-23.
[36] J.T. Brenna, G.Y. Diau. The influence of dietary docosahexaenoic acid and arachidonic acid on central nervous system polyunsaturated fatty acid composition. Prostaglandins Leukot Essent Fatty Acids 77(5-6) (2007) 247-50.
[37] R. Fischer, A. Konkel, H. Mehling, K. Blossey, A. Gapelyuk, N. Wessel, C. von Schacky, R. Dechend, D.N. Muller, M. Rothe, F.C. Luft, K. Weylandt, W.H. Schunck. Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily via the CYP-epoxygenase pathway. J Lipid Res 55(6) (2014) 1150-64.

[38] T.L. Blasbalg, J.R. Hibbeln, C.E. Ramsden, S.F. Majchrzak, R.R. Rawlings. Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. Am J Clin Nutr 93(5) (2011) 950-62.
[39] F. Pinot, D.F. Grant, J.L. Spearow, A.G. Parker, B.D. Hammock. Differential regulation of soluble epoxide hydrolase by clofibrate and sexual hormones in the liver and kidneys of mice. Biochem Pharmacol 50(4) (1995) 501-8.
[40] B.M. De Taeye, C. Morisseau, J. Coyle, J.W. Covington, A. Luria, J. Yang, S.B. Murphy, D.B. Friedman, B.B. Hammock, D.E. Vaughan. Expression and regulation of soluble epoxide hydrolase in adipose tissue. Obesity (Silver Spring) 18(3) (2010) 489-98.
[41] Q. Ren, M. Ma, T. Ishima, C. Morisseau, J. Yang, K.M. Wagner, J.-c. Zhang, C. Yang, W. Yao, C. Dong. Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress. Proceedings of the National Academy of Sciences 113(13) (2016) E1944-E1952.
[42] Q. Ren, M. Ma, J. Yang, R. Nonaka, A. Yamaguchi, K.-i. Ishikawa, K. Kobayashi, S. Murayama, S.H. Hwang, S. Saiki. Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease. Proceedings of the National Academy of Sciences 115(25) (2018) E5815-E5823.
[43] A. Marowsky, J. Burgener, J.R. Falck, J.M. Fritschy, M. Arand. Distribution of soluble and microsomal epoxide hydrolase in the mouse brain and its contribution to cerebral epoxyeicosatrienoic acid metabolism. Neuroscience 163(2) (2009) 646-61.
[44] P. Sura, R. Sura, A.E. Enayetallah, D.F. Grant. Distribution and expression of soluble epoxide hydrolase in human brain. J Histochem Cytochem 56(6) (2008) 551-9.
[45] T.H. Hung, S.K. Shyue, C.H. Wu, C.C. Chen, C.C. Lin, C.F. Chang, S.F. Chen. Deletion or inhibition of soluble epoxide hydrolase protects against brain damage and reduces microglia-mediated neuroinflammation in traumatic brain injury. Oncotarget 8(61) (2017) 103236-103260.
[46] J.E. Gilda, R. Ghosh, J.X. Cheah, T.M. West, S.C. Bodine, A.V. Gomes. Western Blotting Inaccuracies with Unverified Antibodies: Need for a Western Blotting Minimal Reporting Standard (WBMRS). PLoS One 10(8) (2015) e0135392.
[47] S. Rawal, C. Morisseau, B.D. Hammock, A.C. Shivachar. Differential subcellular distribution and colocalization of the microsomal and soluble epoxide hydrolases in cultured neonatal rat brain cortical astrocytes. J Neurosci Res 87(1) (2009) 218-27.
[48] C. Morisseau, J.K. Beetham, F. Pinot, S. Debernard, J.W. Newman, B.D. Hammock. Cress and potato soluble epoxide hydrolases: purification, biochemical characterization, and comparison to mammalian enzymes. Arch Biochem Biophys 378(2) (2000) 321-32.
[49] Y. Zhang, G. Hong, K.S. Lee, B.D. Hammock, D. Gebremedhin, D.R. Harder, R.C. Koehler, A. Sapirstein. Inhibition of soluble epoxide hydrolase augments astrocyte release of vascular endothelial growth factor and neuronal recovery after oxygen-glucose deprivation. J Neurochem 140(5) (2017) 814-825.
[50] S. Guo, S. Wang, W.J. Kim, S.R. Lee, M.P. Frosch, B.J. Bacskai, S.M. Greenberg, E.H. Lo. Effects of apoE isoforms on beta-amyloid-induced matrix metalloproteinase-9 in rat astrocytes. Brain Res 1111(1) (2006) 222-6.
[51] X. Jin, T. Yamashita. Microglia in central nervous system repair after injury. J Biochem 159(5) (2016) 491-6.
[52] M. Ma, Q. Ren, J. Yang, K. Zhang, Z. Xiong, T. Ishima, Y. Pu, S.H. Hwang, M. Toyoshima, Y. Iwayama, Y. Hisano, T. Yoshikawa, B.D. Hammock, K. Hashimoto. Key role of soluble epoxide hydrolase in the neurodevelopmental disorders of offspring after maternal immune activation. Proc Natl Acad Sci U S A 116(14) (2019) 7083-7088.
[53] V.E. Yushmanov, A. Kharlamov, B. Yanovski, G. LaVerde, F.E. Boada, S.C. Jones. Correlated sodium and potassium imbalances within the ischemic core in experimental stroke: a 23Na MRI and histochemical imaging study. Brain Res 1527 (2013) 199-208.
[54] S.E. Khoshnam, W. Winlow, M. Farzaneh, Y. Farbood, H.F. Moghaddam. Pathogenic mechanisms following ischemic stroke. Neurol Sci 38(7) (2017) 1167-1186.

[55] Y. Gan, Q. Liu, W. Wu, J.X. Yin, X.F. Bai, R. Shen, Y. Wang, J. Chen, A. La Cava, J. Poursine-Laurent, W. Yokoyama, F.D. Shi. Ischemic neurons recruit natural killer cells that accelerate brain infarction. Proc Natl Acad Sci U S A 111(7) (2014) 2704-9.
[56] G. del Zoppo, I. Ginis, J.M. Hallenbeck, C. Iadecola, X. Wang, G.Z. Feuerstein. Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol 10(1) (2000) 95-112.
[57] R. Tu, J. Armstrong, K.S.S. Lee, B.D. Hammock, A. Sapirstein, R.C. Koehler. Soluble epoxide hydrolase inhibition decreases reperfusion injury after focal cerebral ischemia. Sci Rep 8(1) (2018) 5279.
[58] W. Zhang, I.P. Koerner, R. Noppens, M. Grafe, H.J. Tsai, C. Morisseau, A. Luria, B.D. Hammock, J.R. Falck, N.J. Alkayed. Soluble epoxide hydrolase: a novel therapeutic target in stroke. J Cereb Blood Flow Metab 27(12) (2007) 1931-40.
[59] A.M. Dorrance, N. Rupp, D.M. Pollock, J.W. Newman, B.D. Hammock, J.D. Imig. An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 46(6) (2005) 842-8.
[60] A.N. Simpkins, R.D. Rudic, D.A. Schreihofer, S. Roy, M. Manhiani, H.J. Tsai, B.D. Hammock, J.D. Imig. Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am J Pathol 174(6) (2009) 2086-95.
[61] J.S. Shaik, M. Ahmad, W. Li, M.E. Rose, L.M. Foley, T.K. Hitchens, S.H. Graham, S.H. Hwang, B.D. Hammock, S.M. Poloyac. Soluble epoxide hydrolase inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is neuroprotective in rat model of ischemic stroke. Am J Physiol Heart Circ Physiol 305(11) (2013) H1605-13.
[62] R. Muralikrishna Adibhatla, J.F. Hatcher. Phospholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. Free Radic Biol Med 40(3) (2006) 376-87.
[63] H.J. Lee, K.S. Kim, I.H. Park, S.U. Kim. Human neural stem cells over-expressing VEGF provide neuroprotection, angiogenesis and functional recovery in mouse stroke model. PLoS One 2(1) (2007) e156.
[64] K.L. Jin, X.O. Mao, D.A. Greenberg. Vascular endothelial growth factor rescues HN33 neural cells from death induced by serum withdrawal. J Mol Neurosci 14(3) (2000) 197-203.
[65] D.Y. Xu, B.B. Davis, Z.H. Wang, S.P. Zhao, B. Wasti, Z.L. Liu, N. Li, C. Morisseau, N. Chiamvimonvat, B.D. Hammock. A potent soluble epoxide hydrolase inhibitor, t-AUCB, acts through PPARgamma to modulate the function of endothelial progenitor cells from patients with acute myocardial infarction. Int J Cardiol 167(4) (2013) 1298-304.
[66] A.U. Hasan, K. Ohmori, K. Konishi, J. Igarashi, T. Hashimoto, K. Kamitori, F. Yamaguchi, I. Tsukamoto, T. Uyama, Y. Ishihara, T. Noma, M. Tokuda, M. Kohno. Eicosapentaenoic acid upregulates VEGF-A through both GPR120 and PPARgamma mediated pathways in 3T3-L1 adipocytes. Mol Cell Endocrinol 406 (2015) 10-8.
[67] L.H. Chang, H.C. Lin, S.S. Huang, I.C. Chen, K.W. Chu, C.L. Chih, Y.W. Liang, Y.C. Lee, Y.Y. Chen, Y.H. Lee, I.H. Lee. Blockade of soluble epoxide hydrolase attenuates post-ischemic neuronal hyperexcitation and confers resilience against stroke with TrkB activation. Sci Rep 8(1) (2018) 118.
[68] X. Tao, A.E. West, W.G. Chen, G. Corfas, M.E. Greenberg. A calcium-responsive transcription factor, CaRF, that regulates neuronal activity-dependent expression of BDNF. Neuron 33(3) (2002) 383-95.
[69] Q.R. Liu, L. Lu, X.G. Zhu, J.P. Gong, Y. Shaham, G.R. Uhl. Rodent BDNF genes, novel promoters, novel splice variants, and regulation by cocaine. Brain Res 1067(1) (2006) 1-12.
[70] A. Chamorro, A. Meisel, A.M. Planas, X. Urra, D. van de Beek, R. Veltkamp. The immunology of acute stroke. Nat Rev Neurol 8(7) (2012) 401-10.
[71] J. Jordan, T. Segura, D. Brea, M.F. Galindo, J. Castillo. Inflammation as therapeutic objective in stroke. Curr Pharm Des 14(33) (2008) 3549-64.
[72] M. Minami, T. Katayama, M. Satoh. Brain cytokines and chemokines: roles in ischemic injury and pain. J Pharmacol Sci 100(5) (2006) 461-70.

[73] K. Node, Y. Huo, X. Ruan, B. Yang, M. Spiecker, K. Ley, D.C. Zeldin, J.K. Liao. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285(5431) (1999) 1276-9.
[74] J.X. Jiang, S.J. Zhang, Y.N. Liu, X.X. Lin, Y.H. Sun, H.J. Shen, X.F. Yan, Q.M. Xie. EETs alleviate ox-LDL-induced inflammation by inhibiting LOX-1 receptor expression in rat pulmonary arterial endothelial cells. Eur J Pharmacol 727 (2014) 43-51.
[75] Q.H. Liu, X. Liu, Z. Wen, B. Hondowicz, L. King, J. Monroe, B.D. Freedman. Distinct calcium channels regulate responses of primary B lymphocytes to B cell receptor engagement and mechanical stimuli. J Immunol 174(1) (2005) 68-79.
[76] H. Watanabe, J. Vriens, J. Prenen, G. Droogmans, T. Voets, B. Nilius. Anandamide and arachidonic acid use epoxyeicosatrienoic acids to activate TRPV4 channels. Nature 424(6947) (2003) 434-8.
[77] D.F. Alvarez, J.A. King, D. Weber, E. Addison, W. Liedtke, M.I. Townsley. Transient receptor potential vanilloid 4-mediated disruption of the alveolar septal barrier: a novel mechanism of acute lung injury. Circ Res 99(9) (2006) 988-95.
[78] S.K. Sonkusare, A.D. Bonev, J. Ledoux, W. Liedtke, M.I. Kotlikoff, T.J. Heppner, D.C. Hill-Eubanks, M.T. Nelson. Elementary Ca2+ signals through endothelial TRPV4 channels regulate vascular function. Science 336(6081) (2012) 597-601.
[79] J. Bystrom, J.A. Wray, M.C. Sugden, M.J. Holness, K.E. Swales, T.D. Warner, M.L. Edin, D.C. Zeldin, D.W. Gilroy, D. Bishop-Bailey. Endogenous epoxygenases are modulators of monocyte/macrophage activity. PLoS One 6(10) (2011) e26591.
[80] D.W. Gilroy, M.L. Edin, R.P. De Maeyer, J. Bystrom, J. Newson, F.B. Lih, M. Stables, D.C. Zeldin, D. Bishop-Bailey. CYP450-derived oxylipins mediate inflammatory resolution. Proc Natl Acad Sci U S A 113(23) (2016) E3240-9.
[81] D.J. DiSabato, N. Quan, J.P. Godbout. Neuroinflammation: the devil is in the details. J Neurochem 139 Suppl 2 (2016) 136-153.
[82] E.C. Hirsch, S. Hunot. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8(4) (2009) 382-97.
[83] P. Teismann, M. Vila, D.K. Choi, K. Tieu, D.C. Wu, V. Jackson-Lewis, S. Przedborski. COX-2 and neurodegeneration in Parkinson's disease. Ann N Y Acad Sci 991 (2003) 272-7.
[84] I. Russo, L. Bubacco, E. Greggio. LRRK2 and neuroinflammation: partners in crime in Parkinson's disease? J Neuroinflammation 11 (2014) 52.
[85] F. Pan-Montojo, O. Anichtchik, Y. Dening, L. Knels, S. Pursche, R. Jung, S. Jackson, G. Gille, M.G. Spillantini, H. Reichmann, R.H. Funk. Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One 5(1) (2010) e8762.
[86] X. Qin, Q. Wu, L. Lin, A. Sun, S. Liu, X. Li, X. Cao, T. Gao, P. Luo, X. Zhu. Soluble epoxide hydrolase deficiency or inhibition attenuates MPTP-induced parkinsonism. Molecular neurobiology 52(1) (2015) 187-195.
[87] J.J. Olearczyk, M.B. Field, I.H. Kim, C. Morisseau, B.D. Hammock, J.D. Imig. Substituted adamantyl-urea inhibitors of the soluble epoxide hydrolase dilate mesenteric resistance vessels. J Pharmacol Exp Ther 318(3) (2006) 1307-14.
[88] T.B. Sherer, R. Betarbet, J.H. Kim, J.T. Greenamyre. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci Lett 341(2) (2003) 87-90.
[89] J.V. Emmrich, T.C. Hornik, J.J. Neher, G.C. Brown. Rotenone induces neuronal death by microglial phagocytosis of neurons. FEBS J 280(20) (2013) 5030-8.
[90] T. Wang, Z. Pei, W. Zhang, B. Liu, R. Langenbach, C. Lee, B. Wilson, J.M. Reece, D.S. Miller, J.S. Hong. MPP+-induced COX-2 activation and subsequent dopaminergic neurodegeneration. FASEB J 19(9) (2005) 1134-6.
[91] N. Lakkappa, P.T. Krishnamurthy, D.P. M, B.D. Hammock, S.H. Hwang. Soluble epoxide hydrolase inhibitor, APAU, protects dopaminergic neurons against rotenone induced neurotoxicity: Implications for Parkinson's disease. Neurotoxicology 70 (2019) 135-145.

[92] J.A. Goldberg, J.N. Guzman, C.M. Estep, E. Ilijic, J. Kondapalli, J. Sanchez-Padilla, D.J. Surmeier. Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson's disease. Nat Neurosci 15(10) (2012) 1414-21.
[93] J. Chen, J.H. Capdevila, D.C. Zeldin, R.L. Rosenberg. Inhibition of cardiac L-type calcium channels by epoxyeicosatrienoic acids. Mol Pharmacol 55(2) (1999) 288-95.
[94] E. Ilijic, J.N. Guzman, D.J. Surmeier. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol Dis 43(2) (2011) 364-71.
[95] A. Vezzani, J. French, T. Bartfai, T.Z. Baram. The role of inflammation in epilepsy. Nat Rev Neurol 7(1) (2011) 31-40.
[96] T. Ravizza, B. Gagliardi, F. Noe, K. Boer, E. Aronica, A. Vezzani. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol Dis 29(1) (2008) 142-60.
[97] A. Mittelman, C. Puccio, E. Gafney, N. Coombe, B. Singh, D. Wood, P. Nadler, T. Ahmed, Z. Arlin. A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion. Invest New Drugs 10(3) (1992) 183-90.
[98] A.A. Shandra, L.S. Godlevsky, R.S. Vastyanov, A.A. Oleinik, V.L. Konovalenko, E.N. Rapoport, N.N. Korobka. The role of TNF-alpha in amygdala kindled rats. Neurosci Res 42(2) (2002) 147-53.
[99] Y.W. Hung, S.W. Hung, Y.C. Wu, L.K. Wong, M.T. Lai, Y.H. Shih, T.S. Lee, Y.Y. Lin. Soluble epoxide hydrolase activity regulates inflammatory responses and seizure generation in two mouse models of temporal lobe epilepsy. Brain Behav Immun 43 (2015) 118-29.
[100] B. Inceoglu, D. Zolkowska, H.J. Yoo, K.M. Wagner, J. Yang, E. Hackett, S.H. Hwang, K.S. Lee, M.A. Rogawski, C. Morisseau, B.D. Hammock. Epoxy fatty acids and inhibition of the soluble epoxide hydrolase selectively modulate GABA mediated neurotransmission to delay onset of seizures. PLoS One 8(12) (2013) e80922.
[101] N.K. Mule, A.C. Orjuela Leon, J.R. Falck, M. Arand, A. Marowsky. 11,12 -Epoxyeicosatrienoic acid (11,12 EET) reduces excitability and excitatory transmission in the hippocampus. Neuropharmacology 123 (2017) 310-321.
[102] H.F. Wu, Y.J. Chen, S.Z. Wu, C.W. Lee, I.T. Chen, Y.C. Lee, C.C. Huang, C.H. Hsing, C.W. Tang, H.C. Lin. Soluble Epoxide Hydrolase Inhibitor and 14,15-Epoxyeicosatrienoic Acid-Facilitated Long-Term Potentiation through cAMP and CaMKII in the Hippocampus. Neural Plast 2017 (2017) 3467805.
[103] B. Garcia-Bueno, J.R. Caso, B.G. Perez-Nievas, P. Lorenzo, J.C. Leza. Effects of peroxisome proliferator-activated receptor gamma agonists on brain glucose and glutamate transporters after stress in rats. Neuropsychopharmacology 32(6) (2007) 1251-60.
[104] R.J. Bridges, C.S. Esslinger. The excitatory amino acid transporters: pharmacological insights on substrate and inhibitor specificity of the EAAT subtypes. Pharmacol Ther 107(3) (2005) 271-85.
[105] N.M. Simon, K. McNamara, C.W. Chow, R.S. Maser, G.I. Papakostas, M.H. Pollack, A.A. Nierenberg, M. Fava, K.K. Wong. A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur Neuropsychopharmacol 18(3) (2008) 230-3.
[106] Y. Dowlati, N. Herrmann, W. Swardfager, H. Liu, L. Sham, E.K. Reim, K.L. Lanctot. A meta-analysis of cytokines in major depression. Biol Psychiatry 67(5) (2010) 446-57.
[107] S.J. Bull, P. Huezo-Diaz, E.B. Binder, J.F. Cubells, G. Ranjith, C. Maddock, C. Miyazaki, N. Alexander, M. Hotopf, A.J. Cleare, S. Norris, E. Cassidy, K.J. Aitchison, A.H. Miller, C.M. Pariante. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry 14(12) (2009) 1095-104.
[108] R.C. Shelton, J. Claiborne, M. Sidoryk-Wegrzynowicz, R. Reddy, M. Aschner, D.A. Lewis, K. Mirnics. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol Psychiatry 16(7) (2011) 751-62.
[109] E. Dale, B. Bang-Andersen, C. Sanchez. Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochem Pharmacol 95(2) (2015) 81-97.
[110] Q. Wu, H. Cai, J. Song, Q. Chang. The effects of sEH inhibitor on depression-like behavior and neurogenesis in male mice. J Neurosci Res 95(12) (2017) 2483-2492.

[111] K.M. Gauthier, C. Deeter, U.M. Krishna, Y.K. Reddy, M. Bondlela, J.R. Falck, W.B. Campbell. 14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res 90(9) (2002) 1028-36.
[112] J. Nunan, D.H. Small. Regulation of APP cleavage by alpha-, beta- and gamma-secretases. FEBS Lett 483(1) (2000) 6-10.
[113] L.M. Ittner, J. Gotz. Amyloid-beta and tau--a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 12(2) (2011) 65-72.
[114] M.R. Minter, J.M. Taylor, P.J. Crack. The contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease. J Neurochem 136(3) (2016) 457-74.
[115] R. Egensperger, S. Kosel, U. von Eitzen, M.B. Graeber. Microglial activation in Alzheimer disease: Association with APOE genotype. Brain Pathol 8(3) (1998) 439-47.
[116] I. Maezawa, N. Maeda, T.J. Montine, K.S. Montine. Apolipoprotein E-specific innate immune response in astrocytes from targeted replacement mice. J Neuroinflammation 3 (2006) 10.
[117] R. Liu, J.Z. Li, J.K. Song, D. Zhou, C. Huang, X.Y. Bai, T. Xie, X. Zhang, Y.J. Li, C.X. Wu, L. Zhang, L. Li, T.T. Zhang, G.H. Du. Pinocembrin improves cognition and protects the neurovascular unit in Alzheimer related deficits. Neurobiol Aging 35(6) (2014) 1275-85.
[118] S.B. Wang, X.B. Pang, M. Gao, L.H. Fang, G.H. Du. Pinocembrin protects rats against cerebral ischemic damage through soluble epoxide hydrolase and epoxyeicosatrienoic acids. Chin J Nat Med 11(3) (2013) 207-13.
[119] E.S. Yao, Y. Tang, X.H. Liu, M.H. Wang. TPPU protects tau from H2O2-induced hyperphosphorylation in HEK293/tau cells by regulating PI3K/AKT/GSK-3beta pathway. J Huazhong Univ Sci Technolog Med Sci 36(6) (2016) 785-790.
[120] M. Liu, Q. Zhu, J. Wu, X. Yu, M. Hu, X. Xie, Z. Yang, J. Yang, Y.Q. Feng, J. Yue. Glutamate affects the production of epoxyeicosanoids within the brain: The up-regulation of brain CYP2J through the MAPK-CREB signaling pathway. Toxicology 381 (2017) 31-38.
[121] Y. Li, J. Wu, X. Yu, S. Na, K. Li, Z. Yang, X. Xie, J. Yang, J. Yue. The Protective Role of Brain CYP2J in Parkinson's Disease Models. Oxid Med Cell Longev 2018 (2018) 2917981.
[122] P. Sarkar, J. Narayanan, D.R. Harder. Differential effect of amyloid beta on the cytochrome P450 epoxygenase activity in rat brain. Neuroscience 194 (2011) 241-9.
[123] R.O. Sanchez-Mejia, J.W. Newman, S. Toh, G.Q. Yu, Y. Zhou, B. Halabisky, M. Cisse, K. Scearce-Levie, I.H. Cheng, L. Gan, J.J. Palop, J.V. Bonventre, L. Mucke. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci 11(11) (2008) 1311-8.
[124] J.J. Rodriguez, V.C. Jones, M. Tabuchi, S.M. Allan, E.M. Knight, F.M. LaFerla, S. Oddo, A. Verkhratsky. Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's disease. PLoS One 3(8) (2008) e2935.
[125] A. Oguro, T. Inoue, S.N. Kudoh, S. Imaoka. 14,15-epoxyeicosatrienoic acid produced by cytochrome P450s enhances neurite outgrowth of PC12 and rat hippocampal neuronal cells. Pharmacol Res Perspect 6(5) (2018) e00428.
[126] H.F. Wu, H.J. Yen, C.C. Huang, Y.C. Lee, S.Z. Wu, T.S. Lee, H.C. Lin. Soluble epoxide hydrolase inhibitor enhances synaptic neurotransmission and plasticity in mouse prefrontal cortex. J Biomed Sci 22 (2015) 94.
[127] N. Sakayori, T. Kikkawa, H. Tokuda, E. Kiryu, K. Yoshizaki, H. Kawashima, T. Yamada, H. Arai, J.X. Kang, H. Katagiri, H. Shibata, S.M. Innis, M. Arita, N. Osumi. Maternal dietary imbalance between omega-6 and omega-3 polyunsaturated fatty acids impairs neocortical development via epoxy metabolites. Stem Cells 34(2) (2016) 470-82.
[128] L. Vallieres, I.L. Campbell, F.H. Gage, P.E. Sawchenko. Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. J Neurosci 22(2) (2002) 486-92.
[129] A.A. Spector, A.W. Norris. Action of epoxyeicosatrienoic acids on cellular function. Am J Physiol Cell Physiol 292(3) (2007) C996-1012.

[130] D. Xu, N. Li, Y. He, V. Timofeyev, L. Lu, H.J. Tsai, I.H. Kim, D. Tuteja, R.K. Mateo, A. Singapuri, B.B. Davis, R. Low, B.D. Hammock, N. Chiamvimonvat. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci U S A 103(49) (2006) 18733-8.
[131] J.A. DiDonato, M. Hayakawa, D.M. Rothwarf, E. Zandi, M. Karin. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 388(6642) (1997) 548-54.
[132] A. Israel. The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb Perspect Biol 2(3) (2010) a000158.
[133] C. Dimitropoulou, L. West, M.B. Field, R.E. White, L.M. Reddy, J.R. Falck, J.D. Imig. Protein phosphatase 2A and Ca2+-activated K+ channels contribute to 11,12-epoxyeicosatrienoic acid analog mediated mesenteric arterial relaxation. Prostaglandins & other lipid mediators 83(1-2) (2007) 50-61.
[134] J.D. Imig, C. Dimitropoulou, D.S. Reddy, R.E. White, J.R. Falck. Afferent arteriolar dilation to 11, 12-EET analogs involves PP2A activity and Ca2+-activated K+ Channels. Microcirculation 15(2) (2008) 137-50.
[135] K.R. Chaudhary, B.N. Zordoky, M.L. Edin, N. Alsaleh, A.O. El-Kadi, D.C. Zeldin, J.M. Seubert. Differential effects of soluble epoxide hydrolase inhibition and CYP2J2 overexpression on postischemic cardiac function in aged mice. Prostaglandins & other lipid mediators 104-105 (2013) 8-17.
[136] J.L. Lahvic, M. Ammerman, P. Li, M.C. Blair, E.R. Stillman, E.M. Fast, A.L. Robertson, C. Christodoulou, J.R. Perlin, S. Yang, N. Chiang, P.C. Norris, M.L. Daily, S.E. Redfield, I.T. Chan, M. Chatrizeh, M.E. Chase, O. Weis, Y. Zhou, C.N. Serhan, L.I. Zon. Specific oxylipins enhance vertebrate hematopoiesis via the receptor GPR132. Proc Natl Acad Sci U S A 115(37) (2018) 9252-9257.
[137] W.Y. Cheng, H. Huynh, P. Chen, S. Pena-Llopis, Y. Wan. Macrophage PPARgamma inhibits Gpr132 to mediate the anti-tumor effects of rosiglitazone. Elife 5 (2016).
[138] D. Katragadda, S.N. Batchu, W.J. Cho, K.R. Chaudhary, J.R. Falck, J.M. Seubert. Epoxyeicosatrienoic acids limit damage to mitochondrial function following stress in cardiac cells. J Mol Cell Cardiol 46(6) (2009) 867-75.
[139] V. Samokhvalov, N. Alsaleh, H.E. El-Sikhry, K.L. Jamieson, C.B. Chen, D.G. Lopaschuk, C. Carter, P.E. Light, R. Manne, J.R. Falck, J.M. Seubert. Epoxyeicosatrienoic acids protect cardiac cells during starvation by modulating an autophagic response. Cell Death Dis 4 (2013) e885.
[140] J. Seubert, B. Yang, J.A. Bradbury, J. Graves, L.M. Degraff, S. Gabel, R. Gooch, J. Foley, J. Newman, L. Mao, H.A. Rockman, B.D. Hammock, E. Murphy, D.C. Zeldin. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res 95(5) (2004) 506-14.
[141] M. Akao, A. Ohler, B. O'Rourke, E. Marban. Mitochondrial ATP-sensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells. Circ Res 88(12) (2001) 1267-75.
[142] B. Inceoglu, A. Bettaieb, F.G. Haj, A.V. Gomes, B.D. Hammock. Modulation of mitochondrial dysfunction and endoplasmic reticulum stress are key mechanisms for the wide-ranging actions of epoxy fatty acids and soluble epoxide hydrolase inhibitors. Prostaglandins & other lipid mediators 133 (2017) 68-78.
[143] M.E. Witte, J.J. Geurts, H.E. de Vries, P. van der Valk, J. van Horssen. Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration? Mitochondrion 10(5) (2010) 411-8.
[144] H.A. Lavoie, S.R. King. Transcriptional regulation of steroidogenic genes: STARD1, CYP11A1 and HSD3B. Exp Biol Med (Maywood) 234(8) (2009) 880-907.
[145] B. Inceoglu, S.L. Jinks, A. Ulu, C.M. Hegedus, K. Georgi, K.R. Schmelzer, K. Wagner, P.D. Jones, C. Morisseau, B.D. Hammock. Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathways. Proc Natl Acad Sci U S A 105(48) (2008) 18901-6.
[146] S. Ren, P. Hylemon, Z.P. Zhang, D. Rodriguez-Agudo, D. Marques, X. Li, H. Zhou, G. Gil, W.M. Pandak. Identification of a novel sulfonated oxysterol, 5-cholesten-3beta,25-diol 3-sulfonate, in hepatocyte nuclei and mitochondria. J Lipid Res 47(5) (2006) 1081-90.
[147] S. Ren, Y. Ning. Sulfation of 25-hydroxycholesterol regulates lipid metabolism, inflammatory responses, and cell proliferation. Am J Physiol Endocrinol Metab 306(2) (2014) E123-30.

[148] X. Chen, Z. Li, B. Zhang, R. Hu, J. Li, M. Feng, W. Yao, C. Zhang, L. Wan, Y. Zhang. Alleviation of Mechanical Allodynia by 14,15-Epoxyeicosatrienoic Acid in a Central Poststroke Pain Model: Possible Role of Allopregnanolone and delta-Subunit-Containing Gamma-Aminobutyric Acid A Receptors. J Pain (2018).
[149] Y. Liu, Y. Zhang, K. Schmelzer, T.S. Lee, X. Fang, Y. Zhu, A.A. Spector, S. Gill, C. Morisseau, B.D. Hammock, J.Y. Shyy. The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Natl Acad Sci U S A 102(46) (2005) 16747-52.
[150] P. Hu, Z. Han, A.D. Couvillon, R.J. Kaufman, J.H. Exton. Autocrine tumor necrosis factor alpha links endoplasmic reticulum stress to the membrane death receptor pathway through IRE1alpha-mediated NF-kappaB activation and down-regulation of TRAF2 expression. Mol Cell Biol 26(8) (2006) 3071-84.
[151] B. Inceoglu, A. Bettaieb, C.A. Trindade da Silva, K.S. Lee, F.G. Haj, B.D. Hammock. Endoplasmic reticulum stress in the peripheral nervous system is a significant driver of neuropathic pain. Proc Natl Acad Sci U S A 112(29) (2015) 9082-7.
[152] A. Bettaieb, N. Nagata, D. AbouBechara, S. Chahed, C. Morisseau, B.D. Hammock, F.G. Haj. Soluble epoxide hydrolase deficiency or inhibition attenuates diet-induced endoplasmic reticulum stress in liver and adipose tissue. J Biol Chem 288(20) (2013) 14189-99.
[153] G. Yu, X. Zeng, H. Wang, Q. Hou, C. Tan, Q. Xu, H. Wang. 14,15-epoxyeicosatrienoic Acid suppresses cigarette smoke extract-induced apoptosis in lung epithelial cells by inhibiting endoplasmic reticulum stress. Cell Physiol Biochem 36(2) (2015) 474-86.
[154] A. Dhanasekaran, S.K. Gruenloh, J.N. Buonaccorsi, R. Zhang, G.J. Gross, J.R. Falck, P.K. Patel, E.R. Jacobs, M. Medhora. Multiple antiapoptotic targets of the PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia. Am J Physiol Heart Circ Physiol 294(2) (2008) H724-35.
[155] P. Hu, Z. Han, A.D. Couvillon, J.H. Exton. Critical role of endogenous Akt/IAPs and MEK1/ERK pathways in counteracting endoplasmic reticulum stress-induced cell death. J Biol Chem 279(47) (2004) 49420-9.
[156] H.X. Geng, R.P. Li, Y.G. Li, X.Q. Wang, L. Zhang, J.B. Deng, L. Wang, J.X. Deng. 14,15-EET Suppresses Neuronal Apoptosis in Ischemia-Reperfusion Through the Mitochondrial Pathway. Neurochem Res 42(10) (2017) 2841-2849.
[157] D. Rodriguez, D. Rojas-Rivera, C. Hetz. Integrating stress signals at the endoplasmic reticulum: The BCL-2 protein family rheostat. Biochim Biophys Acta 1813(4) (2011) 564-74.
[158] E.J. Ryu, H.P. Harding, J.M. Angelastro, O.V. Vitolo, D. Ron, L.A. Greene. Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease. J Neurosci 22(24) (2002) 10690-8.
[159] I. Celardo, A.C. Costa, S. Lehmann, C. Jones, N. Wood, N.E. Mencacci, G.R. Mallucci, S.H. Loh, L.M. Martins. Mitofusin-mediated ER stress triggers neurodegeneration in pink1/parkin models of Parkinson's disease. Cell Death Dis 7(6) (2016) e2271.
[160] T. Katayama, K. Imaizumi, T. Manabe, J. Hitomi, T. Kudo, M. Tohyama. Induction of neuronal death by ER stress in Alzheimer's disease. J Chem Neuroanat 28(1-2) (2004) 67-78.
[161] S. Selvaraj, Y. Sun, J.A. Watt, S. Wang, S. Lei, L. Birnbaumer, B.B. Singh. Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling. J Clin Invest 122(4) (2012) 1354-67.
[162] U. Ozcan, Q. Cao, E. Yilmaz, A.H. Lee, N.N. Iwakoshi, E. Ozdelen, G. Tuncman, C. Gorgun, L.H. Glimcher, G.S. Hotamisligil. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306(5695) (2004) 457-61.
[163] I. Lastres-Becker, F. Molina-Holgado, J.A. Ramos, R. Mechoulam, J. Fernandez-Ruiz. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 19(1-2) (2005) 96-107.

[164] M.N. Hill, B.B. Gorzalka. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol 15(6) (2005) 593-9.
[165] L.E. Wise, A.J. Thorpe, A.H. Lichtman. Hippocampal CB(1) receptors mediate the memory impairing effects of Delta(9)-tetrahydrocannabinol. Neuropsychopharmacology 34(9) (2009) 2072-80.
[166] J. Ehrhart, D. Obregon, T. Mori, H. Hou, N. Sun, Y. Bai, T. Klein, F. Fernandez, J. Tan, R.D. Shytle. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation 2 (2005) 29.
[167] B. Inceoglu, K.R. Schmelzer, C. Morisseau, S.L. Jinks, B.D. Hammock. Soluble epoxide hydrolase inhibition reveals novel biological functions of epoxyeicosatrienoic acids (EETs). Prostaglandins & other lipid mediators 82(1-4) (2007) 42-9.
[168] D.R. McDougle, A. Kambalyal, D.D. Meling, A. Das. Endocannabinoids anandamide and 2-arachidonoylglycerol are substrates for human CYP2J2 epoxygenase. J Pharmacol Exp Ther 351(3) (2014) 616-27.
[169] K. Stark, M. Dostalek, F.P. Guengerich. Expression and purification of orphan cytochrome P450 4X1 and oxidation of anandamide. FEBS J 275(14) (2008) 3706-17.
[170] N.T. Snider, J.A. Nast, L.A. Tesmer, P.F. Hollenberg. A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist. Mol Pharmacol 75(4) (2009) 965-72.
[171] D.R. McDougle, J.E. Watson, A.A. Abdeen, R. Adili, M.P. Caputo, J.E. Krapf, R.W. Johnson, K.A. Kilian, M. Holinstat, A. Das. Anti-inflammatory omega-3 endocannabinoid epoxides. Proc Natl Acad Sci U S A 114(30) (2017) E6034-E6043.
[172] A.A. Rand, P.O. Helmer, B. Inceoglu, B.D. Hammock, C. Morisseau. LC-MS/MS Analysis of the Epoxides and Diols Derived from the Endocannabinoid Arachidonoyl Ethanolamide. Methods Mol Biol 1730 (2018) 123-133.
[173] O. Sasso, K. Wagner, C. Morisseau, B. Inceoglu, B.D. Hammock, D. Piomelli. Peripheral FAAH and soluble epoxide hydrolase inhibitors are synergistically antinociceptive. Pharmacol Res 97 (2015) 7-15.
[174] H. Kawamata, G. Manfredi. Mitochondrial dysfunction and intracellular calcium dysregulation in ALS. Mech Ageing Dev 131(7-8) (2010) 517-26.

Table 1. Studies describing the therapeutic effect of sEH inhibition against neuroinflammatory disorders. Inhibition of sEH is therapeutic in cases of PD, depression, and stroke, while effects on AD and epilepsy are not yet fully elucidated.

Disorder	**Model**	**Therapeutic Effect**	**Behavioral Improvement**	**Treatment**	**Species**	**Reference**
PD	MPTP, Paraquat	Improved TH+ neuron and primary cultured neuron viability	Yes	sEH KO; AUDA (5 mg/kg; i.g.) pre- and post-MPTP; 14,15- and 11,12-EET lateral ventricle injection	Mice	Qin et al. 2015 (86)
	MPTP	Improved DA content and TH+ cell viability, reduced activated microglia	-	sEH KO; TPPU (0.3, 1.0, or 3.0 mg/kg; p.o.)	Mice	Ren et al. 2018 (42)
	Rotenone	Reduced dopaminergic neuron viability and inflammatory markers, increased redox gene expression	Yes	APAU (50, 100, 250 μM; DW)	Drosophila	Lakkappa et al. 2019 (91)
Epilepsy	Pilocarpine, amygdala kindling	Reduced inflammatory cytokines, reduced number and duration of seizures with AUDA	Yes	sEH KO, AUDA (10 mg/kg; i.n.) once daily 30 min prior; TPPU (0.5, 1 and 1.5 mg/kg; i.n.)	Mice	Hung et al. 2015 (99)
	Picrotoxin, Pentylenetetrazol	Increased PTZ seizure threshold, delayed seizure onset, reduced tonic seizure	Yes	sEH KO; EpFAs (0.5 μg; i.c.v.); TUPS/TPPU (0.1 or 1 μg; i.c.v)	Mice	Inceoglu et al. 2013 (100)
Depression	Social defeat stress, LPS	Reduced depression-like behavior and inflammatory cytokine	Yes	sEH KO; TPPU (0.3, 1.0, or 3.0 mg/kg; p.o.)	Mice	Ren et al. 2016 (102)
	Social defeat	Reduced depression-like behavior and increased neurogenesis	Yes	TPPU (0.01 - 0.1 mg/kg; i.p.)	Mice	Wu et al. 2017 (103)
Stroke	MCAO	Reduced infarct size and neural death, decreased inflammatory cytokines	Yes	TPPU (1 mg/kg; i.p) after 90 min	Rats	Tu et al. 2018 (57)

	MCAO	Reduced infarct size	-	AUDA-BE (10 mg/kg; i.p.) 30 min prior and at repurfusion	Mice	Zhang et al. 2007 (58)
	MCAO	Reduced infarct size	-	AUDA (25 mg/L; DW) 6 weeks	Rats (SHSRP)	Dorrance et al. 2005 (59)
	MCAO	Reduced infarct size, improved vasculature	-	AUDA (50 mg/L; DW) 6 weeks ; *t*-AUCB (50 mg/L; DW) 5 weeks	Rats (SHSRP; WKY)	Simpkins et al. 2009 (60)
	MCAO	Reduced infarct size, improved vasculature	Yes	*t*-AUCB (0.9 mg/kg; i.v.)	Rats	Shaik et al. 2013 (61)
	MCAO	Reduced infarct size, reduced glial activation, increased pTrkB	Yes	sEH KO; AUDA (10 mg/kg; i.p.) 7 consecutive days post-MCAO	Mice	Chang et al. 2018 (67)
Other	TBI	Reduced contusion volume, hemispheric enlargement ratio, neural death, neutrophil infiltration, microglial activation, and inflammatory cytokine/chemokine inflammatory; improved BBB integrity	Yes	sEH KO, AUDA (10 μM in 0.5 μL); intracerebroventricular injection 30 min prior	Mice	Hung et al. 2017 (45)
	Zymosan	Alteration in monocyte recruitment, chemokine expression, and cytokine expression	-	sEH KO; SKF525A (30mg/kg; i.p.)	Mice	Gilroy et al. 2016 (80)

Table 2. Potential mechanisms of the therapeutic effect of EETs and/or sEH inhibition. While CYP metabolites of EPA or DHA are also known to have therapeutic effects, their mechanisms are not included in this table.

Model	**Treatment**	**Mechanism**	**Species/Cell Type**	**Reference**
H_2O_2	TPPU (0, 0.1, 1, 10 μmol/L)	Decreased tau phosphorylation, increased phosphorylation of Akt and GSK-3β	HEK293 transfected with tau	Yao et al. 2016 (119)
Hypoxia	EETs (1 μM)	Increased activity of PI3K and phosphorylation of Akt	Myocytes	Dhanasekaran et al. 2008 (154)
OGD	TPPU (100 μM); *t*-AUCB (100 μM)	Increased expression of VEGF and phosphorylation of Akt	Primary rat neurons and astrocytes	Zhang et al. 2017 (49)
-	*t*-AUCB (1 - 100 μM)	Increased expression of VEGF	Endothelial projenitor cells	Xu et al. 2013(65)
Social defeat, LPS	sEH KO; TPPU (0.3, 1.0, or 3.0 mg/kg, p.o.)	Increased mature BDNF and p-TrkB	Mice	Ren et al. 2016 (102)
Social defeat	TPPU (0.01 - 0.1 mg/kg, i.p.)	Increased BDNF expression and therapeutic effect through Trk	Mice	Wu et al. 2017 (103)
MCAO	sEH KO; AUDA (10 mg/kg, i.p.)	Increased mature BDNF and p-TrkB	Mice	Chang et al. 2018 (67)
-	5,6-EET	Activation of NSCC	Mice B cells	Liu et al. 2005 (75)
-	11,12-EET (2 μM)	Activation of GIRK	Mice hippocampal slices	Mule et al. 2017 (101)
-	EETs and HETEs	Activation of TRPV4	PC12 cells	Oguro et al. 2018 (125)
-	11,12-EET (20, 125 nM); 14,15-EET	Inhibition of L-type Ca^{2+} channel	Porcine cardiac muscle cell membrane	Chen et al. 1998 (93)
-	CYP2J2	Activation of mitoK_{ATP} and increased phospho-p42/p44 MAPK	Human cardiomyocytes	Seubert et al. 2004 (140)
Streptozocin	TPPU (10 mg/kg, i.p.)	Reduced expression of ER stress markers	Rats	Inceoglu et al. 2015 (151)
Thapsigargain, palmitate, high fat diet	sEH KO; TUPS (10 μg/ml, DW); EpFAs	Reduced expression of ER stress markers	Mice, HEPG2 cells, 3T3-L1 cells	Bettaieb et al. 2013 (152)

MPTP	sEH KO; TPPU (0.3, 1.0, or 3.0 mg/kg; p.o.)	Reduced expression of ER stress markers	Mice	Ren et al. 2018 (42)
Cigarette smoke extract	14,15-EET (1 μM)	Reduced expression of ER stress markers	Human bronchial endothelial cells	Yu et al. 2015 (153)
-	EETs and Linolaic epoxides	Increased β-arrestin recruitment by GPR132	-	Lahvic et al. 2018 (136)
Cytokine Stimulation	14,15- and 11,12-EET (1 - 100 nM)	Reduction in adhesion molecules, regulation of NF-κB through inhibition of IKK activity	Human endothelial cells	Node et al. 1999 (73)
ox-LDL	14,15- and 11,12-EET (1 μM)	Regulation of NF-κB	Pulmonary artery endothelial cells	Jiang et al. 2014 (74)
Pilocarpine, amygdala kindling	sEH KO, AUDA (10 mg/kg, i.n.); TPPU (0.5, 1 and 1.5 mg/kg, i.n.)	Regulation of NF-κB	Mice	Hung et al. 2015 (99)
IL-1β	8,9-EET and 11,12-EET (1 μM), CYP2J2	Regulation of NF-κB, involvement of PPAR-α	HEK293 cells	Bystrom et al. 2011 (79)
Ascending aortic constriction	AEPU (0.1 mg/ml, DW) 3 weeks; AUDA	Increased expression and decreased phosphorylation of IκBα, regulation of NF-κB	Mice	Xu et al. 2006 (130)
LPS	AEPU (0.1, 1, 3 μg); TPAU (0.1 - 10 mg/kg); EETs (5 μg)	Increased StAR expression	Rats	Inceoglu et al. 2008 (145)
-	AUDA (1 μM); EETs (5 - 100 μM)	Binding and regulation of PPAR-γ	Endothelial cells	Liu et al. 2005 (149)

Figure 1

Click here to access/download;Figure;Slide1.TIF



Figure 2

Click here to access/download;Figure;Slide2.TIF



Figure 3

Click here to access/download;Figure;Slide3.TIF